Prof Saye Khoo MB,BS, MRCP, DTM&H, FRCP, MD, Diploma in Epidemiology

Professor(Clin, Hcc) Molecular and Clinical Pharmacology

    Publications

    2019

    TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. (Journal article)

    Pushpakom, S., Kolamunnage-Dona, R., Taylor, C., Foster, T., Spowart, C., García-Fiñana, M., . . . TAILoR Study Group. (2019). TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. doi:10.1093/cid/ciz589

    DOI: 10.1093/cid/ciz589

    Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat. (Journal article)

    Elliot, E. R., Bisdomini, E., Penchala, S. D., Khoo, S., Nwokolo, N., & Boffito, M. (2019). Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat.. HIV research & clinical practice, 1-10. doi:10.1080/25787489.2019.1638077

    DOI: 10.1080/25787489.2019.1638077

    Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects (Journal article)

    Mofenson, L. M., Pozniak, A. L., Wambui, J., Raizes, E., Ciaranello, A., Clayden, P., . . . Ford, N. P. (2019). Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 22(7). doi:10.1002/jia2.25352

    DOI: 10.1002/jia2.25352

    Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine" (Journal article)

    Walimbwa, S., Lamorde, M., Waitt, C., Amara, A., & Khoo, S. (2019). Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(6). doi:10.1128/AAC.00593-19

    DOI: 10.1128/AAC.00593-19

    A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV (Journal article)

    Cranston, R. D., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . McGowan, I. (2019). A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS RESEARCH AND HUMAN RETROVIRUSES, 35(9), 794-804. doi:10.1089/aid.2018.0265

    DOI: 10.1089/aid.2018.0265

    Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial (Journal article)

    Banda, C. G., Chaponda, M., Mukaka, M., Mulenga, M., Hachizovu, S., Kabuya, J. B., . . . Mwapasa, V. (2019). Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial. MALARIA JOURNAL, 18. doi:10.1186/s12936-019-2818-7

    DOI: 10.1186/s12936-019-2818-7

    British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019 (Report)

    Bracchi, M., van Halsema, C., Post, F., Awosusi, F., Barbour, A., Bradley, S., . . . Pozniak, A. (2019). British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. doi:10.1111/hiv.12748

    DOI: 10.1111/hiv.12748

    Carbamazepine intervention in a patient with efavirenz-induced liver injury (Journal article)

    Jacobs, T. G., Burger, D. M., Pranger, A. D., Khoo, S. H., Drenth, J. P. H., & van Crevel, R. (2019). Carbamazepine intervention in a patient with efavirenz-induced liver injury. AIDS, 33(6), 1097-1098. doi:10.1097/QAD.0000000000002116

    DOI: 10.1097/QAD.0000000000002116

    The role of raltegravir alone or combined with lamivudine as PrEP: a phase 2 randomised controlled clinical trial (Conference Paper)

    Fox, J., Herrera, C., Lwanga, J., Lee, M., Else, L., Amara, A., . . . Dickenson, L. (2019). The role of raltegravir alone or combined with lamivudine as PrEP: a phase 2 randomised controlled clinical trial. In HIV MEDICINE Vol. 20 (pp. 5-6). Retrieved from http://gateway.webofknowledge.com/

    The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis (Journal article)

    Duwal, S., Seeler, D., Dickinson, L., Khoo, S., & von Kleist, M. (2019). The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. FRONTIERS IN PHARMACOLOGY, 10. doi:10.3389/fphar2019.00199

    DOI: 10.3389/fphar2019.00199

    The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. (Journal article)

    Duwal, S., Seeler, D., Dickinson, L., Khoo, S., & von Kleist, M. (2019). The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis.. Frontiers in pharmacology, 10, 199. doi:10.3389/fphar.2019.00199

    DOI: 10.3389/fphar.2019.00199

    Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019) (Journal article)

    Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(5), 1466. doi:10.1093/jac/dky571

    DOI: 10.1093/jac/dky571

    Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics (Journal article)

    Gini, J., Olagunju, A., Dickinson, L., Waitt, C., Neary, M., Else, L. J., . . . Khoo, S. (2019). Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. PHARMACOGENOMICS, 20(4), 217-224. doi:10.2217/pgs-2018-0111

    DOI: 10.2217/pgs-2018-0111

    Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis. (Journal article)

    Duwal, S., Dickinson, L., Khoo, S., & von Kleist, M. (2019). Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis.. PLoS computational biology, 15(1), e1006740. doi:10.1371/journal.pcbi.1006740

    DOI: 10.1371/journal.pcbi.1006740

    HIV-Related Arterial Stiffness in Malawian Adults Is Associated With the Proportion of PD-1–Expressing CD8+ T Cells and Reverses With Antiretroviral Therapy (Journal article)

    Kelly, C., Mwandumba, H. C., Heyderman, R. S., Jambo, K., Kamng'ona, R., Chammudzi, M., . . . Khoo, S. (2019). HIV-Related Arterial Stiffness in Malawian Adults Is Associated With the Proportion of PD-1–Expressing CD8+ T Cells and Reverses With Antiretroviral Therapy. The Journal of infectious diseases. doi:10.1093/infdis/jiz015

    DOI: 10.1093/infdis/jiz015

    Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction? (Journal article)

    Abdullahi, S. T., Olagunju, A., Soyinka, J. O., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2019). Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?. British journal of clinical pharmacology. doi:10.1111/bcp.13821

    DOI: 10.1111/bcp.13821

    Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers. (Journal article)

    Elliot, E. R., Cerrone, M., Else, L., Amara, A., Bisdomini, E., Khoo, S., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.. The Journal of antimicrobial chemotherapy, 74(1), 149-156. doi:10.1093/jac/dky384

    DOI: 10.1093/jac/dky384

    2018

    Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. (Journal article)

    Decloedt, E. H., Sinxadi, P. Z., van Zyl, G. U., Wiesner, L., Khoo, S., Joska, J. A., . . . Maartens, G. (2018). Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.. The Journal of antimicrobial chemotherapy. doi:10.1093/jac/dky481

    DOI: 10.1093/jac/dky481

    Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk (Journal article)

    Gini, J., Penchala, S. D., Amara, A., Challenger, E., Egan, D., Waitt, C., . . . Else, L. J. (2018). Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. BIOANALYSIS, 10(23), 1933-1945. doi:10.4155/bio-2018-0085

    DOI: 10.4155/bio-2018-0085

    Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria. (Journal article)

    Gini, J., Amara, A., Penchala, S. D., Back, D. J., Else, L., Egan, D., . . . Khoo, S. H. (2018). Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.. International journal of STD & AIDS, 956462418809749. doi:10.1177/0956462418809749

    DOI: 10.1177/0956462418809749

    Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine (Journal article)

    Walimbwa, S. I., Lamorde, M., Waitt, C., Kaboggoza, J., Else, L., Byakika-Kibwika, P., . . . Khoo, S. H. (2019). Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(2). doi:10.1128/AAC.01310-18

    DOI: 10.1128/AAC.01310-18

    Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment (Conference Paper)

    Alagaratnam, J., Dilly-Penchala, S., Challenger, E., Else, L., Legg, K., Petersen, C., . . . Winston, A. (2019). Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 85 (pp. 1039-1040). doi:10.1111/bcp.13878

    DOI: 10.1111/bcp.13878

    Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT (Conference Paper)

    Nash, S., Herrera, C., Serwanga, J., Ruzagira, E., O'Hagan, K., Kelly, C., . . . Fox, J. (2018). Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT. In AIDS RESEARCH AND HUMAN RETROVIRUSES Vol. 34 (pp. 364). Retrieved from http://gateway.webofknowledge.com/

    Novel online drug-drug interaction resource reveals clinically relevant interactions in > 20% of the searches (Conference Paper)

    Lankheet, N. A. G., Ferrier, K. R. M., Gibbons, S. E., Burger, D. M., McAllister, K., Martin, J. L. M., . . . Jansman, F. G. (2018). Novel online drug-drug interaction resource reveals clinically relevant interactions in > 20% of the searches. In ANNALS OF ONCOLOGY Vol. 29. Retrieved from http://gateway.webofknowledge.com/

    Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV (Conference Paper)

    Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from http://gateway.webofknowledge.com/

    Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid (Spain): a population-based study (Conference Paper)

    Lopez-Centeno, B., Badenes-Olmedo, C., Mataix-Sanjuan, A., McAllister, K., Bellon-Cano, J., Balsalobre, P., . . . Berenguer, J. (2018). Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid (Spain): a population-based study. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from http://gateway.webofknowledge.com/

    Using Climate-HIV to describe non-antiretroviral use and potential DDIs for people living with HIV within a UK cohort (Conference Paper)

    Okoli, C., Khoo, S., Schwenk, A., Radford, M., Myland, M., Taylor, S., . . . Benn, P. (2018). Using Climate-HIV to describe non-antiretroviral use and potential DDIs for people living with HIV within a UK cohort. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from http://gateway.webofknowledge.com/

    Two cases of monkeypox imported to the United Kingdom, September 2018 (Journal article)

    Vaughan, A., Aarons, E., Astbury, J., Balasegaram, S., Beadsworth, M., Beck, C. R., . . . Wilburn, J. (2018). Two cases of monkeypox imported to the United Kingdom, September 2018. EUROSURVEILLANCE, 23(38), 2-6. doi:10.2807/1560-7917.ES.2018.23.38.1800509

    DOI: 10.2807/1560-7917.ES.2018.23.38.1800509

    Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy (Journal article)

    Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(11). doi:10.1128/AAC.01162-18

    DOI: 10.1128/AAC.01162-18

    Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters (Journal article)

    Danjuma, M. I., Egan, D., Abubeker, I. Y., Post, F., & Khoo, S. (2018). Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters. INTERNATIONAL JOURNAL OF STD & AIDS, 29(14), 1384-1389. doi:10.1177/0956462418786562

    DOI: 10.1177/0956462418786562

    High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily (Journal article)

    Seden, K., Kiiza, D., Laker, E., Arinaitwe, W. J., Waitt, C., Lamorde, M., & Khoo, S. (2018). High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(11), 3158-3161. doi:10.1093/jac/dky298

    DOI: 10.1093/jac/dky298

    Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults (Journal article)

    Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(8). doi:10.1128/AAC.00634-18

    DOI: 10.1128/AAC.00634-18

    Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults. (Journal article)

    Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.. Antimicrobial agents and chemotherapy, 62(8). doi:10.1128/AAC.00634-18

    DOI: 10.1128/AAC.00634-18

    DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy (Conference Paper)

    Orrell, C., Kintu, K., Coombs, J. A., Amara, A., Myer, L., Kaboggoza, J., . . . Grp, D. S. (2018). DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21 (pp. 166). Retrieved from http://gateway.webofknowledge.com/

    Development of a drug-drug interaction website to support prescribing of oncolytics (Conference Paper)

    Ferrier, K., Jansman, F., Burger, D., McAllister, K., Gibbons, S., Khoo, S., . . . Lankheet, N. (2018). Development of a drug-drug interaction website to support prescribing of oncolytics. In INTERNATIONAL JOURNAL OF CLINICAL PHARMACY Vol. 40 (pp. 735-736). Retrieved from http://gateway.webofknowledge.com/

    Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes (Journal article)

    Duwal, S., Dickinson, L., Khoo, S., & von Kleist, M. (2018). Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. PLOS COMPUTATIONAL BIOLOGY, 14(6). doi:10.1371/journal.pcbi.1006155

    DOI: 10.1371/journal.pcbi.1006155

    Development of an online drug-drug interaction resource to support safe prescription of oncolytics. (Conference Paper)

    Van Erp, N. P., Ferrier, K. R. M., Gibbons, S. E., Burger, D., McAllister, K., Martin, J. L. M., . . . Lankheet, N. A. G. (2018). Development of an online drug-drug interaction resource to support safe prescription of oncolytics.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.e18574

    DOI: 10.1200/JCO.2018.36.15_suppl.e18574

    Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults (Journal article)

    Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00412-18

    DOI: 10.1128/AAC.00412-18

    Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding (Journal article)

    Olagunju, A., Rajoli, R. K. R., Atoyebi, S. A., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research. doi:10.12688/aasopenres.12860.1

    DOI: 10.12688/aasopenres.12860.1

    The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. (Journal article)

    Smolders, E. J., Willemse, S. B., El-Sherif, O., Khoo, S., & Burger, D. M. (2018). The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.. Annals of hepatology, 17(3), 525-529. doi:10.5604/01.3001.0011.7398

    DOI: 10.5604/01.3001.0011.7398

    Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications (Journal article)

    Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18

    DOI: 10.1128/AAC.00717-18

    Plasma NRTI concentrations and renal function in people with HIV (Conference Paper)

    Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI concentrations and renal function in people with HIV. In HIV MEDICINE Vol. 19 (pp. S16-S17). Retrieved from http://gateway.webofknowledge.com/

    Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39) (Journal article)

    Imaz, A., Niubo, J., Amara, A., Khoo, S., Ferrer, E., Tiraboschi, J. M., . . . Podzamczer, D. (2018). Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39). JOURNAL OF NEUROVIROLOGY, 24(4), 391-397. doi:10.1007/s13365-018-0626-4

    DOI: 10.1007/s13365-018-0626-4

    Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma (Journal article)

    Cirrincione, L. R., Penchala, S. D., Scarsi, K. K., Podany, A. T., Winchester, L. C., Back, D. J., . . . Else, L. J. (2018). Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084, 106-112. doi:10.1016/j.jchromb.2018.03.023

    DOI: 10.1016/j.jchromb.2018.03.023

    ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma. (Conference Paper)

    Elliot, E., Neary, M. G., Else, L., Khoo, S., Moyle, G., Carr, D., . . . Boffito, M. (n.d.). ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma.. In CROI. Boston, MA, USA.

    Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals (Journal article)

    Mora-Peris, B., Bouliotis, G., Ranjababu, K., Clarke, A., Post, F. A., Nelson, M., . . . Winston, A. (2018). Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals. AIDS, 32(8), 1007-1015. doi:10.1097/QAD.0000000000001786

    DOI: 10.1097/QAD.0000000000001786

    Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy (Journal article)

    Ruggiero, A., Cozzi-Lepri, A., Beloukas, A., Richman, D., Khoo, S., Phillips, A., . . . Grp, E. R. A. S. S. (2018). Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy. OPEN FORUM INFECTIOUS DISEASES, 5(2). doi:10.1093/ofid/ofy032

    DOI: 10.1093/ofid/ofy032

    Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications (Journal article)

    Marra, F., zu Siederdissen, C. H., Khoo, S., Back, D., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Cornberg, M. (2018). Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(5), 961-971. doi:10.1111/bcp.13519

    DOI: 10.1111/bcp.13519

    Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs (Journal article)

    Waitt, C., Olagunju, A., Nakalema, S., Kyohaire, I., Owen, A., Lamorde, M., & Khoo, S. (2018). Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(4), 1013-1019. doi:10.1093/jac/dkx507

    DOI: 10.1093/jac/dkx507

    HIV infection and stroke. (Journal article)

    Benjamin, L., & Khoo, S. (2018). HIV infection and stroke.. Handbook of clinical neurology, 152, 187-200. doi:10.1016/b978-0-444-63849-6.00015-3

    DOI: 10.1016/b978-0-444-63849-6.00015-3

    2017

    A first-in-human study of the novel HIV-fusion inhibitor C34-PEG(4)-Chol (Journal article)

    Quinn, K., Traboni, C., Penchala, S. D., Bouliotis, G., Doyle, N., Libri, V., . . . Winston, A. (2017). A first-in-human study of the novel HIV-fusion inhibitor C34-PEG(4)-Chol. SCIENTIFIC REPORTS, 7. doi:10.1038/s41598-017-09230-0

    DOI: 10.1038/s41598-017-09230-0

    Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study (Journal article)

    Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. Retrieved from http://gateway.webofknowledge.com/

    Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals (Journal article)

    Jackson, A., Else, L., Higgs, C., Karolia, Z., Khoo, S., Back, D., . . . Boffito, M. (2018). Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals. HIV CLINICAL TRIALS, 19(1), 31-37. doi:10.1080/15284336.2017.1408928

    DOI: 10.1080/15284336.2017.1408928

    Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme. (Conference Paper)

    El-Sherif, O., Pertinez, H., Irving, W., Penchala, S. D., McLauchlan, J., Foster, G. R., . . . Khoo, S. (2017). Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme.. In HEPATOLOGY Vol. 66 (pp. 831A-832A). Retrieved from http://gateway.webofknowledge.com/

    Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling (Journal article)

    Olagunju, A., Schipani, A., Bolaji, O., Khoo, S., & Owen, A. (2018). Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(1), 165-172. doi:10.1093/jac/dkx334

    DOI: 10.1093/jac/dkx334

    Development of an online drug-drug interaction resource to support prescribing of oncolytics (Conference Paper)

    Lankheet, N. A. G., Jansman, F. G., Gibbons, S. E., Burger, D. M., McAllister, K., Khoo, S. H., & Van Erp, N. P. (2017). Development of an online drug-drug interaction resource to support prescribing of oncolytics. In ANNALS OF ONCOLOGY Vol. 28. Retrieved from http://gateway.webofknowledge.com/

    An open-label multiple-dose phase 1 assessment of long-acting rilpivirine (Conference Paper)

    McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . Cranston, R. D. (2017). An open-label multiple-dose phase 1 assessment of long-acting rilpivirine. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 20 (pp. 31). Retrieved from http://gateway.webofknowledge.com/

    Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017) (Journal article)

    Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2143. doi:10.1093/jac/dkx145

    DOI: 10.1093/jac/dkx145

    Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS (Journal article)

    Waitt, C., Penchala, S. D., Olagunju, A., Amara, A., Else, L., Lamorde, M., & Khoo, S. (2017). Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1060, 300-307. doi:10.1016/j.jchromb.2017.06.012

    DOI: 10.1016/j.jchromb.2017.06.012

    Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis. (Journal article)

    Sloan, D. J., McCallum, A. D., Schipani, A., Egan, D., Mwandumba, H. C., Ward, S. A., . . . Davies, G. R. (2017). Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00210-17

    DOI: 10.1128/aac.00210-17

    Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro. (Journal article)

    Roberts, O., Khoo, S., Owen, A., & Siccardi, M. (2017). Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(5). doi:10.1128/AAC.01776-16

    DOI: 10.1128/aac.01776-16

    Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries (Journal article)

    Seden, K., Boffito, M., & Khoo, S. (2017). Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries. CURRENT OPINION IN HIV AND AIDS, 12(4), 377-382. doi:10.1097/COH.0000000000000384

    DOI: 10.1097/COH.0000000000000384

    Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (Journal article)

    Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2035-2041. doi:10.1093/jac/dkx108

    DOI: 10.1093/jac/dkx108

    Case report: atazanavir associated cholelithiasis (Conference Paper)

    Howlett, P., Simons, R., Wilkinson, M., Kulasegaram, R., Elsie, L., & Khoo, S. (2017). Case report: atazanavir associated cholelithiasis. In HIV MEDICINE Vol. 18 (pp. 15). Retrieved from http://gateway.webofknowledge.com/

    Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population (Journal article)

    Carr, D. F., Bourgeois, S., Chaponda, M., Takeshita, L. Y., Morris, A. P., Castro, E. M. C., . . . Pirmohamed, M. (2017). Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(4), 1152-1162. doi:10.1093/jac/dkw545

    DOI: 10.1093/jac/dkw545

    Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection (Journal article)

    Seden, K., Gibbons, S., Marzolini, C., Schapiro, J. M., Burger, D. M., Back, D. J., & Khoo, S. H. (2017). Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLOS ONE, 12(3). doi:10.1371/journal.pone.0173509

    DOI: 10.1371/journal.pone.0173509

    ELITA consensus statements on use of DAAs in liver transplant candidates and recipients. (Journal article)

    Belli, L. S., Duvoux, C., Berenguer, M., Berg, T., Coilly, A., Colle, I., . . . Strazzabosco, M. (2017). ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. JOURNAL OF HEPATOLOGY, 67(3), 585-602. doi:10.1016/j.jhep.2017.03.006

    DOI: 10.1016/j.jhep.2017.03.006

    ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine. (Conference Paper)

    Bracchi, M., Neary, M. G., Pagani, N., Else, L., Khoo, S., Abbas, Z., . . . Boffito, M. (n.d.). ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.. In CROI. Seattle, WA, USA.

    Impact of polypharmacy on antiretroviral prescription in people living with HIV (Journal article)

    Guaraldi, G., Menozzi, M., Zona, S., Calcagno, A., Silva, A. R., Santoro, A., . . . Khoo, S. H. (2017). Impact of polypharmacy on antiretroviral prescription in people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(2), 511-514. doi:10.1093/jac/dkw437

    DOI: 10.1093/jac/dkw437

    Estimated generic prices for novel treatments for drug-resistant tuberculosis (Journal article)

    Gotham, D., Fortunak, J., Pozniak, A., Khoo, S., Cooke, G., III, N. F. E., & Hill, A. (2017). Estimated generic prices for novel treatments for drug-resistant tuberculosis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(4), 1243-1252. doi:10.1093/jac/dkw522

    DOI: 10.1093/jac/dkw522

    Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies (Conference Paper)

    Marra, F., Siederdissen, C. H. Z., Khoo, S., Cornberg, M., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Back, D. (2017). Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S314). Retrieved from http://gateway.webofknowledge.com/

    Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women (Journal article)

    Khoo, S., Peytavin, G., Burger, D., Hill, A., Brown, K., Moecklinghoff, C., . . . Hadacek, M. B. (2017). Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women. AIDS REVIEWS, 19(1), 16-23. Retrieved from http://gateway.webofknowledge.com/

    2016

    Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment (Journal article)

    McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., . . . Cranston, R. D. (2016). Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. LANCET HIV, 3(12), E569-E578. doi:10.1016/S2352-3018(16)30113-8

    DOI: 10.1016/S2352-3018(16)30113-8

    Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. (Journal article)

    Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.. Journal of acquired immune deficiency syndromes (1999), 73(3), 252-257. doi:10.1097/qai.0000000000001108

    DOI: 10.1097/qai.0000000000001108

    Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis (Journal article)

    Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 73(3), 252-257. Retrieved from http://gateway.webofknowledge.com/

    Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study (Journal article)

    McCallum, A. D., Nyirenda, D., Lora, W., Khoo, S. H., Sloan, D. J., Mwandumba, H. C., . . . Davies, G. R. (2016). Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study. PLOS ONE, 11(10). doi:10.1371/journal.pone.0165734

    DOI: 10.1371/journal.pone.0165734

    Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch (Conference Paper)

    Dickinson, L., Bracchi, M., Elliot, E., Else, L., Khoo, S., Back, D., . . . Boffito, M. (2016). Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from http://gateway.webofknowledge.com/

    Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice (Conference Paper)

    Elliot, E., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2016). Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from http://gateway.webofknowledge.com/

    British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (Journal article)

    Churchill, D., Waters, L., Ahmed, N., Angus, B., Boffito, M., Bower, M., . . . Grp, W. (2016). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV MEDICINE, 17, S2-S104. doi:10.1111/hiv.12426

    DOI: 10.1111/hiv.12426

    Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study (Journal article)

    Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227

    DOI: 10.1097/FPC.0000000000000227

    The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma (Journal article)

    Penchala, S. D., Fawcett, S., Else, L., Egan, D., Amara, A., Elliot, E., . . . Khoo, S. (2016). The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1027, 174-180. doi:10.1016/j.jchromb.2016.05.040

    DOI: 10.1016/j.jchromb.2016.05.040

    Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis (Journal article)

    Nightingale, S., Chau, T. T. H., Fisher, M., Nelson, M., Winston, A., Else, L., . . . Grp, P. -V. S. (2016). Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(8), 4511-4518. doi:10.1128/AAC.00280-16

    DOI: 10.1128/AAC.00280-16

    CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF (Journal article)

    Nightingale, S., Michael, B. D., Fisher, M., Winston, A., Nelson, M., Taylor, S., . . . Solomon, T. (2016). CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. CYTOKINE, 83, 139-146. doi:10.1016/j.cyto.2016.04.004

    DOI: 10.1016/j.cyto.2016.04.004

    Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications (Journal article)

    Marzolini, C., Gibbons, S., Khoo, S., & Back, D. (2016). Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(7), 1755-1758. doi:10.1093/jac/dkw032

    DOI: 10.1093/jac/dkw032

    Persistence of rilpivirine following single dose of long-acting injection (Conference Paper)

    McGowan, I., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., Edick, S., . . . Cranston, R. D. (2016). Persistence of rilpivirine following single dose of long-acting injection. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from http://gateway.webofknowledge.com/

    Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis (Journal article)

    Olagunju, A., Khoo, S., & Owen, A. (2016). Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. PHARMACOGENOMICS, 17(8), 891-906. doi:10.2217/pgs-2015-0016

    DOI: 10.2217/pgs-2015-0016

    Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease (Journal article)

    Molto, J., Graterol, F., Miranda, C., Khoo, S., Bancu, I., Amara, A., . . . Clotet, B. (2016). Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(4), 2564-2566. doi:10.1128/AAC.03131-15

    DOI: 10.1128/AAC.03131-15

    Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia (Journal article)

    Nightingale, S., Geretti, A. M., Beloukas, A., Fisher, M., Winston, A., Else, L., . . . Khoo, S. (2016). Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. JOURNAL OF NEUROVIROLOGY, 22(6), 852-860. doi:10.1007/s13365-016-0448-1

    DOI: 10.1007/s13365-016-0448-1

    Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing (Journal article)

    Lewis, J. M., Railton, E., Riordan, A., Khoo, S., & Chaponda, M. (2016). Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS, 30(8), 1313-1315. doi:10.1097/QAD.0000000000001055

    DOI: 10.1097/QAD.0000000000001055

    A first-in-human study, in HIV-positive men, of the novel HIV-fusion inhibitor C34-PEG4-Chol (Journal article)

    Quinn, K., Bouliotis, G., Doyle, N., Winston, A., Ashby, D., Weber, J., . . . Pessi, A. (2016). A first-in-human study, in HIV-positive men, of the novel HIV-fusion inhibitor C34-PEG4-Chol. HIV MEDICINE, 17, 18. Retrieved from http://gateway.webofknowledge.com/

    Adequacy of Rifampin Absorption after Jejunostomy Tube Administration (Journal article)

    Stott, K. E., Singh, B., Beadsworth, M. B. J., Vaudrey, K., Khoo, S. H., & Davies, G. (2016). Adequacy of Rifampin Absorption after Jejunostomy Tube Administration. PHARMACOTHERAPY, 36(4), E23-E25. doi:10.1002/phar.1730

    DOI: 10.1002/phar.1730

    Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake (Journal article)

    Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425

    DOI: 10.1093/jac/dkv425

    Single dose Maraviroc provides high drug levels in all sites; no gender differences (Journal article)

    Tiraboschi, J., Davies, O., Fox, J., Else, L., Egan, D., Amara, A., . . . Boffito, M. (2016). Single dose Maraviroc provides high drug levels in all sites; no gender differences. HIV MEDICINE, 17, 17. Retrieved from http://gateway.webofknowledge.com/

    Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. (Journal article)

    Fox, J., Brady, M., Alexander, H., Davies, O., Robinson, N., Pace, M., . . . Frater, J. (2016). Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports.. Infectious diseases and therapy, 5(1), 65-71. doi:10.1007/s40121-015-0102-x

    DOI: 10.1007/s40121-015-0102-x

    First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB (Journal article)

    Lewis, J. M., Hine, P., Walker, J., Khoo, S. H., Taegtmeyer, M., Squire, S. B., & Sloan, D. J. (2016). First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. EUROPEAN RESPIRATORY JOURNAL, 47(5), 1581-1584. doi:10.1183/13993003.01980-2015

    DOI: 10.1183/13993003.01980-2015

    Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro (Conference Paper)

    Roberts, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016). Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro. In CROI. Boston, USA.

    Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know? (Journal article)

    Vitoria, M., Hill, A. M., Ford, N. P., Doherty, M., Khoo, S. H., & Pozniak, A. L. (2016). Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 19. doi:10.7448/IAS.19.1.20504

    DOI: 10.7448/IAS.19.1.20504

    DETERMINATION OF LEDIPASVIR CONCENTRATIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS RECEIVING LOW DOSE PROTON PUMP INHIBITORS DURING SOFOSBUVIR-LEDIPASVIR TREATMENT FOR HCV GENOTYPE 1 INFECTION (Conference Paper)

    El-Sherif, O., Stewart, S., Bergin, C., McKiernan, S., Crosbie, O., Khoo, S., & Norris, S. (2016). DETERMINATION OF LEDIPASVIR CONCENTRATIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS RECEIVING LOW DOSE PROTON PUMP INHIBITORS DURING SOFOSBUVIR-LEDIPASVIR TREATMENT FOR HCV GENOTYPE 1 INFECTION. In JOURNAL OF HEPATOLOGY Vol. 64 (pp. S805-S806). doi:10.1016/S0168-8278(16)01573-7

    DOI: 10.1016/S0168-8278(16)01573-7

    Dosing antiretroviral medication when crossing time zones: a review (Journal article)

    Lewis, J. M., Volny-Anne, A., Waitt, C., Boffito, M., & Khoo, S. (2016). Dosing antiretroviral medication when crossing time zones: a review. AIDS, 30(2), 267-271. doi:10.1097/QAD.0000000000000920

    DOI: 10.1097/QAD.0000000000000920

    2015

    Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study (Journal article)

    Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5

    DOI: 10.1007/s40262-015-0360-5

    Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach (Journal article)

    Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1041-1045. doi:10.1093/jac/dkv439

    DOI: 10.1093/jac/dkv439

    Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus (Journal article)

    van de Ven, N., Fortunak, J., Simmons, B., Ford, N., Cooke, G. S., Khoo, S., & Hill, A. (2015). Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus. HEPATOLOGY, 61(4), 1174-1182. doi:10.1002/hep.27641

    DOI: 10.1002/hep.27641

    Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers (Journal article)

    Seng, K. -Y., Hee, K. -H., Soon, G. -H., Chew, N., Khoo, S. H., & Lee, L. S. -U. (2015). Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(11), 6791-6799. doi:10.1128/AAC.01244-15

    DOI: 10.1128/AAC.01244-15

    Determination of on-treatment pharmacokinetics of sofosbuvir and ledipasvir in patients with decompensated cirrhosis - the need for real world PK studies (Conference Paper)

    El-Sherif, O., Houlihan, D. D., Stewart, S., Bergin, C. J., Fanning, L. J., McKiernan, S., . . . Khoo, S. H. (2015). Determination of on-treatment pharmacokinetics of sofosbuvir and ledipasvir in patients with decompensated cirrhosis - the need for real world PK studies. In HEPATOLOGY Vol. 62 (pp. 752A). Retrieved from http://gateway.webofknowledge.com/

    Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study (Journal article)

    Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Grp, E. S. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. CLINICAL PHARMACOLOGY & THERAPEUTICS, 98(4), 406-416. doi:10.1002/cpt.156

    DOI: 10.1002/cpt.156

    Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation (Journal article)

    Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15

    DOI: 10.1128/AAC.01441-15

    Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots (Journal article)

    Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174

    DOI: 10.1093/jac/dkv174

    Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection (Journal article)

    El-Sherif, O., Khoo, S., & Solas, C. (2015). Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection. CURRENT OPINION IN HIV AND AIDS, 10(5), 348-354. doi:10.1097/COH.0000000000000185

    DOI: 10.1097/COH.0000000000000185

    Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety (Journal article)

    Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D., & Boffito, M. (2015). Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety. AIDS, 29(13), 1585-1592. doi:10.1097/QAD.0000000000000786

    DOI: 10.1097/QAD.0000000000000786

    Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis (Journal article)

    Sloan, D. J., Mwandumba, H. C., Garton, N. J., Khoo, S. H., Butterworth, A. E., Allain, T. J., . . . Davies, G. R. (2015). Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. Clinical Infectious Diseases, 61(1), 1-8. doi:10.1093/cid/civ195

    DOI: 10.1093/cid/civ195

    Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain. (Journal article)

    Rokx, C., Richman, D. D., Müller-Trutwin, M., Silvestri, G., Lunzen, J., Khoo, S., . . . Boucher, C. A. (2015). Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.. Journal of virus eradication, 1(3), 211-220.

    Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study (Journal article)

    Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.

    Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy: need for "real world" PK studies to identify vulnerable populations (Journal article)

    El-Sherif, O., Dilly, P. S., Else, L., McKiernan, S., Khoo, S., & Norris, S. (2015). Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy: need for "real world" PK studies to identify vulnerable populations. IRISH JOURNAL OF MEDICAL SCIENCE, 184, S218. Retrieved from http://gateway.webofknowledge.com/

    Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis (Journal article)

    Cummins, N. W., Neuhaus, J., Chu, H., Neaton, J., Wyen, C., Rockstroh, J. K., . . . Grp, I. N. S. I. G. H. T. S. (2015). Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBIOMEDICINE, 2(7), 706-712. doi:10.1016/j.ebiom.2015.05.012

    DOI: 10.1016/j.ebiom.2015.05.012

    Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults (Journal article)

    Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(5), 1482-1486. doi:10.1093/jac/dku575

    DOI: 10.1093/jac/dku575

    Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study (Journal article)

    Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. CLINICAL INFECTIOUS DISEASES, 61(3), 453-463. doi:10.1093/cid/civ317

    DOI: 10.1093/cid/civ317

    Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies (Journal article)

    Waitt, C. J., Garner, P., Bonnett, L. J., Khoo, S. H., & Else, L. J. (2015). Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(7), 1928-1941. doi:10.1093/jac/dkv080

    DOI: 10.1093/jac/dkv080

    A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1 (Journal article)

    Tiraboschi, J., Fox, J., Herrera, C., Olejniczak, N., Jackson, A., Boffito, M., . . . Shattock, R. (2015). A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1. HIV MEDICINE, 16, 3-4. Retrieved from http://gateway.webofknowledge.com/

    A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry (Journal article)

    Amara, A. B., Else, L. J., Tjia, J., Olagunju, A., Puls, R. L., Khoo, S., & Back, D. J. (2015). A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry. THERAPEUTIC DRUG MONITORING, 37(2), 220-228. doi:10.1097/FTD.0000000000000127

    DOI: 10.1097/FTD.0000000000000127

    CSF:plasma HIV-1 RNA discordance > 0.5 log(10) is associated with raised inflammatory mediator profiles in CSF (Journal article)

    Nightingale, S., Michael, B., King, S., Beloukas, A., Pirmohamed, M., Geretti, A. M., . . . Post, F. (2015). CSF:plasma HIV-1 RNA discordance > 0.5 log(10) is associated with raised inflammatory mediator profiles in CSF. HIV MEDICINE, 16, 7. Retrieved from http://gateway.webofknowledge.com/

    Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial (Journal article)

    Winston, A., Amin, J., Clarke, A., Else, L., Amara, A., Owen, A., . . . CSF, E. C. F. (2015). Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 60(7), 1026-1032. doi:10.1093/cid/ciu976

    DOI: 10.1093/cid/ciu976

    Developing a new virtual HIV network: Our region's experience (Journal article)

    Wolujewicz, A., Lewis, J., Chaponda, M., Chiong, J., & Khoo, S. (2015). Developing a new virtual HIV network: Our region's experience. HIV MEDICINE, 16, 69-70. Retrieved from http://gateway.webofknowledge.com/

    Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis (Journal article)

    Sloan, D. J., Mwandumba, H. C., Garton, N. J., Khoo, S. H., Butterworth, A. E., Allain, T. J., . . . Davies, G. R. (2015). Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. CLINICAL INFECTIOUS DISEASES, 61(1), 1-8. doi:10.1093/cid/civ195

    DOI: 10.1093/cid/civ195

    Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort (Journal article)

    Lewis, J. M., Stott, K. E., Monnery, D., Seden, K., Beeching, N. J., Chaponda, M., . . . Beadsworth, M. B. J. (2016). Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort. INTERNATIONAL JOURNAL OF STD & AIDS, 27(2), 105-109. doi:10.1177/0956462415574632

    DOI: 10.1177/0956462415574632

    A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS (Journal article)

    Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Graham, C., . . . Winston, A. (2015). A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS. SEXUALLY TRANSMITTED INFECTIONS, 91, A78. doi:10.1136/sextrans-2015-052126.231

    DOI: 10.1136/sextrans-2015-052126.231

    A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers (Journal article)

    Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Cooke, G., . . . Winston, A. (2015). A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1812-1815. doi:10.1093/jac/dkv035

    DOI: 10.1093/jac/dkv035

    A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children (Journal article)

    Schipani, A., Pertinez, H., Mlota, R., Molyneux, E., Lopez, N., Dzinjalamala, F. K., . . . Davies, G. (2016). A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 81(4), 679-687. doi:10.1111/bcp.12848

    DOI: 10.1111/bcp.12848

    Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics (Journal article)

    Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43

    DOI: 10.1002/cpt.43

    Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults (Journal article)

    Seng, K. -Y., Hee, K. -H., Soon, G. -H., Chew, N., Khoo, S. H., & Lee, L. S. -U. (2015). Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3298-3306. doi:10.1093/jac/dkv268

    DOI: 10.1093/jac/dkv268

    Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial (Journal article)

    McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., . . . Gill, O. N. (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. LANCET, 387(10013), 53-60. doi:10.1016/S0140-6736(15)00056-2

    DOI: 10.1016/S0140-6736(15)00056-2

    Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda (Journal article)

    Seden, K., Merry, C., Hewson, R., Siccardi, M., Lamorde, M., Byakika-Kibwika, P., . . . Khoo, S. H. (2015). Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3317-3322. doi:10.1093/jac/dkv259

    DOI: 10.1093/jac/dkv259

    Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults (Journal article)

    Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother, 70(5), 1482-1486.

    Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy (Journal article)

    Pushpakom, S. P., Taylor, C., Kolamunnage-Dona, R., Spowart, C., Vora, J., Garcia-Finana, M., . . . Pirmohamed, M. (2015). Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. BMJ OPEN, 5(10). doi:10.1136/bmjopen-2015-009566

    DOI: 10.1136/bmjopen-2015-009566

    Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine (Journal article)

    Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8

    DOI: 10.1007/s40262-014-0184-8

    Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes (Journal article)

    Sloan, D. J., Mwandumba, H. C., Kamdolozi, M., Shani, D., Chisale, B., Dutton, J., . . . Davies, G. R. (2015). Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 19(8), 904-911. doi:10.5588/ijtld.15.0071

    DOI: 10.5588/ijtld.15.0071

    Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes (Journal article)

    Sloan, D. J., Mwandumba, H. C., Kamdolozi, M., Shani, D., Chisale, B., Dutton, J., . . . Davies, G. R. (2015). Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes. The International Journal of Tuberculosis and Lung Disease, 19(8), 904-911. doi:10.5588/ijtld.15.0071

    DOI: 10.5588/ijtld.15.0071

    2014

    RISK FACTORS AND THERAPEUTIC IMPLICATIONS OF VITAMIN D DEFICIENCY IN MALAWIAN ADULTS WITH PULMONARY TUBERCULOSIS (Conference Paper)

    Sloan, D. J., Guwende, C., Banda, G., Shani, D., Kamdolozi, M., Chisale, B., . . . Davies, G. R. (2014). RISK FACTORS AND THERAPEUTIC IMPLICATIONS OF VITAMIN D DEFICIENCY IN MALAWIAN ADULTS WITH PULMONARY TUBERCULOSIS. In THORAX Vol. 69 (pp. A42). doi:10.1136/thoraxjnl-2014-206260.81

    DOI: 10.1136/thoraxjnl-2014-206260.81

    Controversies in HIV-associated neurocognitive disorders (Journal article)

    Nightingale, S., Winston, A., Letendre, S., Michael, B. D., McArthur, J. C., Khoo, S., & Solomon, T. (2014). Controversies in HIV-associated neurocognitive disorders. LANCET NEUROLOGY, 13(11), 1139-1151. doi:10.1016/S1474-4422(14)70137-1

    DOI: 10.1016/S1474-4422(14)70137-1

    Darunavir pharmacokinetics throughout pregnancy and postpartum (Journal article)

    Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc, 17(4 Supp), 19485.

    Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant (Journal article)

    Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc, 17(4 Supp), 19484.

    Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant (Journal article)

    Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 4. doi:10.7448/IAS.17.4.19484

    DOI: 10.7448/IAS.17.4.19484

    No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals (Journal article)

    Singh, G. J., Jackson, A., D'Avolio, A., Else, L., De Nicolo, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. AIDS, 28(13), 1993-1995. doi:10.1097/QAD.0000000000000356

    DOI: 10.1097/QAD.0000000000000356

    CYP2B6 c.983T > C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations (Journal article)

    Carr, D. F., Chaponda, M., Castro, E. M. C., Jorgensen, A. L., Khoo, S., Van Oosterhout, J. J., . . . Pirmohamed, M. (2014). CYP2B6 c.983T > C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(12), 3329-3334. doi:10.1093/jac/dku315

    DOI: 10.1093/jac/dku315

    Hepatitis B Virus Sub-genotype A1 Infection Is Characterized by High Replication Levels and Rapid Emergence of Drug Resistance in HIV-Positive Adults Receiving First-line Antiretroviral Therapy in Malawi (Journal article)

    Aoudjane, S., Chaponda, M., del Castillo, A. A. G., O'Connor, J., Noguera, M., Beloukas, A., . . . Geretti, A. M. (2014). Hepatitis B Virus Sub-genotype A1 Infection Is Characterized by High Replication Levels and Rapid Emergence of Drug Resistance in HIV-Positive Adults Receiving First-line Antiretroviral Therapy in Malawi. CLINICAL INFECTIOUS DISEASES, 59(11), 1618-1626. doi:10.1093/cid/ciu630

    DOI: 10.1093/cid/ciu630

    Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers (Journal article)

    Singh, G. K. J., Jackson, A., D'Avolio, A., Else, L., Bonora, S., Di Perri, G., . . . Boffito, M. (2014). Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers. HIV MEDICINE, 15, 115. Retrieved from http://gateway.webofknowledge.com/

    Who accesses PrEP? An analysis of baseline data in the PROUD pilot (Journal article)

    Dolling, D., Desai, M., Saunders, J., Mackie, N., McOwan, A., Youssef, E., . . . Study, P. R. O. U. D. (2014). Who accesses PrEP? An analysis of baseline data in the PROUD pilot. HIV MEDICINE, 15, 15. Retrieved from http://gateway.webofknowledge.com/

    Abacavir Forms Novel Cross-Linking Abacavir Protein Adducts in Patients (Journal article)

    Meng, X., Lawrenson, A. S., Berry, N. G., Maggs, J. L., French, N. S., Back, D. J., . . . Park, B. K. (2014). Abacavir Forms Novel Cross-Linking Abacavir Protein Adducts in Patients. CHEMICAL RESEARCH IN TOXICOLOGY, 27(4), 524-535. doi:10.1021/tx400406p

    DOI: 10.1021/tx400406p

    A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops (Journal article)

    Lewis, J., Turtle, L., Khoo, S., & Nsutebu, E. (2014). A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. AIDS, 28(17), 2636-2637. doi:10.1097/QAD.0000000000000462

    DOI: 10.1097/QAD.0000000000000462

    Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro-In Vivo Correlation (Journal article)

    McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Smith, D., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro-In Vivo Correlation. ADVANCED HEALTHCARE MATERIALS, 3(3), 400-411. doi:10.1002/adhm.201300280

    DOI: 10.1002/adhm.201300280

    Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity (Journal article)

    Yombi, J. C., Pozniak, A., Boffito, M., Jones, R., Khoo, S., Levy, J., & Post, F. A. (2014). Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS, 28(5), 621-632. doi:10.1097/QAD.0000000000000103

    DOI: 10.1097/QAD.0000000000000103

    CYP3A4*22 (c.522-191 C > T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults (Journal article)

    Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). CYP3A4*22 (c.522-191 C > T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073

    DOI: 10.1097/FPC.0000000000000073

    Darunavir pharmacokinetics throughout pregnancy and postpartum (Poster)

    Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. Poster session presented at the meeting of Unknown Conference. Retrieved from http://gateway.webofknowledge.com/

    DOI: 10.7448/IAS.17.4.19485

    Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS (Journal article)

    Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420

    DOI: 10.1093/jac/dku420

    Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection (Journal article)

    Karageorgopoulos, D. E., El-Sherif, O., Bhagani, S., & Khoo, S. H. (2014). Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. CURRENT OPINION IN INFECTIOUS DISEASES, 27(1), 36-45. doi:10.1097/QCO.0000000000000034

    DOI: 10.1097/QCO.0000000000000034

    Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. (Presentation material)

    Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.. doi:10.7448/IAS.17.4.19484

    DOI: 10.7448/IAS.17.4.19484

    Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir (Journal article)

    Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 550-554. doi:10.1093/jac/dku376

    DOI: 10.1093/jac/dku376

    HIV Associated Neurocognitive Disorders (HAND) in Malawian Adults and Effect on Adherence to Combination Anti-Retroviral Therapy: A Cross Sectional Study (Journal article)

    Kelly, C. M., van Oosterhout, J. J., Ngwalo, C., Stewart, R. C., Benjamin, L., Robertson, K. R., . . . Solomon, T. (2014). HIV Associated Neurocognitive Disorders (HAND) in Malawian Adults and Effect on Adherence to Combination Anti-Retroviral Therapy: A Cross Sectional Study. PLOS ONE, 9(6). doi:10.1371/journal.pone.0098962

    DOI: 10.1371/journal.pone.0098962

    Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries (Journal article)

    Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014). Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. CLINICAL INFECTIOUS DISEASES, 58(7), 928-936. doi:10.1093/cid/ciu012

    DOI: 10.1093/cid/ciu012

    Minimum target prices for production of Direct Acting Antivirals and associated diagnostics for developing countries (Conference Paper)

    Hill, A. M., van de Ven, N. S., Simmons, B., Ford, N., Khoo, S. H., & Fortunak, J. M. (2014). Minimum target prices for production of Direct Acting Antivirals and associated diagnostics for developing countries. In HEPATOLOGY Vol. 60 (pp. 233A-234A). Retrieved from http://gateway.webofknowledge.com/

    No pharmacokinetic interaction between raltegravir and amlodipine (Journal article)

    Singh, G. J., Jackson, A., D’Avolio, A., Else, L., De Nicolò, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine. AIDS, 28(13), 1993-1995. doi:10.1097/QAD.0000000000000356

    DOI: 10.1097/QAD.0000000000000356

    Open source clinical science for emerging infections (Journal article)

    Dunning, J. W., Merson, L., Rohde, G. G. U., Gao, Z., Semple, M. G., Tran, D., . . . Council, I. S. A. R. I. C. (2014). Open source clinical science for emerging infections. LANCET INFECTIOUS DISEASES, 14(1), 8-9. doi:10.1016/S1473-3099(13)70327-X

    DOI: 10.1016/S1473-3099(13)70327-X

    Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients (Journal article)

    Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(2), 491-499. doi:10.1093/jac/dkt372

    DOI: 10.1093/jac/dkt372

    Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome (Journal article)

    Sloan, D. J., Schipani, A., Waterhouse, D., Stone, L., Mwandumba, H. C., Butterworth, A. E., . . . Davies, G. R. (2014). Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome. Topics in Antiviral Medicine, 22(e-1), 55. Retrieved from https://www.iasusa.org/tam/april-2014

    Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry (Journal article)

    Else, L. J., Tjia, J., Jackson, A., Penchala, S. D., Egan, D., Boffito, M., . . . Back, D. J. (2014). Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry. BIOANALYSIS, 6(14), 1907-1921. doi:10.4155/BIO.14.59

    DOI: 10.4155/BIO.14.59

    Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy (Journal article)

    Mora-Peris, B., Watson, V., Vera, J. H., Weston, R., Waldman, A. D., Kaye, S., . . . Winston, A. (2014). Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(6), 1642-1647. doi:10.1093/jac/dku018

    DOI: 10.1093/jac/dku018

    Severe virologic expression of hepatitis B virus (HBV) co-infection in HIV-positive adults starting antiretroviral therapy (ART) in Malawi (Conference Paper)

    Geretti, A. M., Aoudjane, S., Chaponda, M., Gonzalez del Castillo, A., O'Connor, J., Noguera, M., . . . van Oosterhout, J. (2014). Severe virologic expression of hepatitis B virus (HBV) co-infection in HIV-positive adults starting antiretroviral therapy (ART) in Malawi. In ANTIVIRAL THERAPY Vol. 19 (pp. A36). Retrieved from http://gateway.webofknowledge.com/

    Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors? (Journal article)

    Hill, A., Khoo, S., Back, D., Pozniak, A., & Boffito, M. (2014). Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. J Int AIDS Soc, 17(4 Supp), 19583.

    Should the dose of tenofovir be reduced to 200-250mg/day, when combined with protease inhibitors? (Journal article)

    Hill, A., Khoo, S., Back, D., Pozniak, A., & Boffito, M. (2014). Should the dose of tenofovir be reduced to 200-250mg/day, when combined with protease inhibitors?. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 64-65. doi:10.7448/IAS.17.4.19583

    DOI: 10.7448/IAS.17.4.19583

    Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy - need for "real world" PK studies to identify vulnerable populations (Conference Paper)

    El-Sherif, O., Penchala, S. D., Else, L. J., Norris, S., & Khoo, S. H. (2014). Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy - need for "real world" PK studies to identify vulnerable populations. In HEPATOLOGY Vol. 60 (pp. 689A). Retrieved from http://gateway.webofknowledge.com/

    Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach (Journal article)

    Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. J Int AIDS Soc, 17(4 Supp), 19586.

    Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach (Journal article)

    Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 67. doi:10.7448/IAS.17.4.19586

    DOI: 10.7448/IAS.17.4.19586

    Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. (Journal article)

    Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.. Journal of the International AIDS Society, 17(4 Suppl 3), 19586. doi:10.7448/IAS.17.4.19586

    DOI: 10.7448/IAS.17.4.19586

    Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update) (Journal article)

    Williams, I., Churchill, D., Anderson, J., Boffito, M., Bower, M., Cairns, G., . . . Grp, W. (2014). Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update). HIV MEDICINE, 15, 1-85. doi:10.1111/hiv.12119

    DOI: 10.1111/hiv.12119

    Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy (Journal article)

    Else, L., Jackson, V., Brennan, M., Back, D., Khoo, S., Coulter-Smith, S., & Lambert, J. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV Medicine, n/a. doi:10.1111/hiv.12164

    DOI: 10.1111/hiv.12164

    2013

    Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. (Journal article)

    Mora-Peris, B., Croucher, A., Else, L. J., Vera, J. H., Khoo, S., Scullard, G., . . . Winston, A. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.. The Journal of antimicrobial chemotherapy, 68(6), 1348-1353. doi:10.1093/jac/dkt006

    DOI: 10.1093/jac/dkt006

    Rilpivirine concentrations in seminal plasma in HIV infected patients (Poster)

    Watson, V., Mora-Peris, B., Tjia, J., Vera, J. H., Weston, R., Khoo, S., . . . Winston, A. (2013). Rilpivirine concentrations in seminal plasma in HIV infected patients. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.

    Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach (Conference Paper)

    Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.

    Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England (Journal article)

    Seden, K., Kirkham, J. J., Kennedy, T., Lloyd, M., James, S., McManus, A., . . . Khoo, S. (2013). Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ Open, 3(1).

    An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database) (Journal article)

    Danjuma, M. I., Mohamad-Fadzillah, N. H., & Khoo, S. (2014). An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database). INTERNATIONAL JOURNAL OF STD & AIDS, 25(4), 273-279. doi:10.1177/0956462413504747

    DOI: 10.1177/0956462413504747

    Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population (Journal article)

    Carr, D. F., Chaponda, M., Jorgensen, A. L., Castro, E. C., van Oosterhout, J. J., Khoo, S. H., . . . Pirmohamed, M. (2013). Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. CLINICAL INFECTIOUS DISEASES, 56(9), 1330-1339. doi:10.1093/cid/cit021

    DOI: 10.1093/cid/cit021

    Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England (Journal article)

    Seden, K., Kirkham, J. J., Kennedy, T., Lloyd, M., James, S., Mcmanus, A., . . . Khoo, S. H. (2013). Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ OPEN, 3(1). doi:10.1136/bmjopen-2012-002036

    DOI: 10.1136/bmjopen-2012-002036

    Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases. (Journal article)

    Seden, K., Khoo, S., Back, D., Prevatt, N., Lamorde, M., Byakika-Kibwika, P., . . . Merry, C. (2013). Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases.. AIDS (London, England), 27(5), 675-686. doi:10.1097/qad.0b013e32835ca9b4

    DOI: 10.1097/qad.0b013e32835ca9b4

    Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. (Journal article)

    Winston, A., Jose, S., Gibbons, S., Back, D., Stohr, W., Post, F., . . . UK Collaborative HIV Cohort Study. (2013). Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.. The Journal of antimicrobial chemotherapy, 68(6), 1354-1359. doi:10.1093/jac/dkt029

    DOI: 10.1093/jac/dkt029

    Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. (Journal article)

    Seden, K., Khoo, S. H., Back, D., Byakika-Kibwika, P., Lamorde, M., Ryan, M., & Merry, C. (2013). Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.. The Journal of antimicrobial chemotherapy, 68(1), 1-3. doi:10.1093/jac/dks346

    DOI: 10.1093/jac/dks346

    Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation (Journal article)

    Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225

    DOI: 10.1093/jac/dkt225

    Kidney transplantation in HIV-positive adults: the UK experience (Journal article)

    Gathogo, E. N., Hamzah, L., Hilton, R., Marshall, N., Ashley, C., Harber, M., . . . Stud, U. K. H. I. V. K. T. (2014). Kidney transplantation in HIV-positive adults: the UK experience. INTERNATIONAL JOURNAL OF STD & AIDS, 25(1), 57-66. doi:10.1177/0956462413493266

    DOI: 10.1177/0956462413493266

    Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment (Journal article)

    Lamorde, M., Byakika-Kibwika, P., Mayito, J., Nabukeera, L., Ryan, M., Hanpithakpong, W., . . . Merry, C. (2013). Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS, 27(6), 961-965. doi:10.1097/QAD.0b013e32835cae3b

    DOI: 10.1097/QAD.0b013e32835cae3b

    New Drugs and Treatment Regimens for tuberculosis (Journal article)

    Sloan, D. J., Davies, G. R., & Khoo, S. H. (2013). New Drugs and Treatment Regimens for tuberculosis. Current Respiratory Medicine Reviews, 9(3), 200-210.

    Opinion: The Pharmacometrics of Infectious Disease (Journal article)

    Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacometrics & Systems Pharmacology, 2(8), e70. doi:10.1038/psp.2013.46

    DOI: 10.1038/psp.2013.46

    Opinion: the pharmacometrics of infectious disease. (Journal article)

    Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: the pharmacometrics of infectious disease.. CPT: pharmacometrics & systems pharmacology, 2, e70. doi:10.1038/psp.2013.46

    DOI: 10.1038/psp.2013.46

    Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi (Journal article)

    Dickinson, L., Chaponda, M., Carr, D. F., van Oosterhout, J. J., Kumwenda, J., Lalloo, D. G., . . . Khoo, S. H. (2014). Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(2), 706-712. doi:10.1128/AAC.02069-13

    DOI: 10.1128/AAC.02069-13

    Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach (Journal article)

    Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7

    DOI: 10.1007/s40262-013-0056-7

    Recent advances in tuberculosis: New drugs and treatment regimens (Journal article)

    Sloan, D., Davies, G., & Khoo, S. (2013). Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev, 9(3), 200-210.

    Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies (Journal article)

    Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231

    DOI: 10.1097/QAI.0b013e3182737231

    Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies (Journal article)

    Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231

    DOI: 10.1097/QAI.0b013e3182737231

    The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence (Journal article)

    Seden, K., Bradley, M., Miller, A. R. O., Beadsworth, M. B. J., & Khoo, S. H. (2013). The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence. International Journal of STD & AIDS, 24(3), 237-241. doi:10.1177/0956462412472428

    DOI: 10.1177/0956462412472428

    The pharmacometrics of infectious diseases (Journal article)

    Davies, G. R., Khoo, S. H., & Hope, W. (2013). The pharmacometrics of infectious diseases. CPT: Pharmacometrics and systems pharmacology, 2, e70. Retrieved from cpt:%20pharmacomet.%20syst.%20pharmacol.%202:%20e70;%20doi:10.1038/psp.2013.46

    Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients (Journal article)

    Westwood, T. D., Hogan, C., Julyan, P. J., Coutts, G., Bonington, S., Carrington, B., . . . Bonington, A. (2013). Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. European Journal of Radiology, 82(8), e374-e379. doi:10.1016/j.ejrad.2013.03.008

    DOI: 10.1016/j.ejrad.2013.03.008

    Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer (Journal article)

    Penchala, S. D., Tjia, J., El Sherif, O., Back, D. J., Khoo, S. H., & Else, L. J. (2013). Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 932, 100-110. doi:10.1016/j.jchromb.2013.06.013

    DOI: 10.1016/j.jchromb.2013.06.013

    2012

    Development and validation of a LC-MS/MS assay to quantify intracellular tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) (Journal article)

    Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify intracellular tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP). Journal of the International AIDS Society, 15(6(Suppl 4)). doi:10.7448/IAS.15.6.18336

    DOI: 10.7448/IAS.15.6.18336

    Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose (Journal article)

    Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Boffito, M., . . . Back, D. (2012). Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose. Journal of the International AIDS Society, 15(4).

    Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF) (Poster)

    Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.

    Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)

    Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.

    Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. (Journal article)

    Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.

    Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)

    Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82e

    DOI: 10.1097/FPC.0b013e32834dd82e

    British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. (Journal article)

    Williams, I., Churchill, D., Anderson, J., Boffito, M., Bower, M., Cairns, G., . . . Youle, M. (2012). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.. HIV medicine, 13 Suppl 2, 1-85. doi:10.1111/j.1468-1293.2012.01029.x

    DOI: 10.1111/j.1468-1293.2012.01029.x

    Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. (Journal article)

    Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., . . . Merry, C. (2012). Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.. Chemotherapy Research and Practice.

    Divalent Metals and pH Alter Raltegravir Disposition In Vitro (Journal article)

    Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition In Vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11

    DOI: 10.1128/AAC.06407-11

    Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults (Journal article)

    Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. AIDS Research and Treatment, 2012, 1-6. doi:10.1155/2012/105980

    DOI: 10.1155/2012/105980

    Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)

    Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095

    DOI: 10.3851/IMP2095

    Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)

    Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.

    HIV infection and stroke: current perspectives and future directions (Journal article)

    Benjamin, L. A., Bryer, A., Emsley, H. C. A., Khoo, S., Solomon, T., & Connor, M. D. (2012). HIV infection and stroke: current perspectives and future directions. LANCET NEUROLOGY, 11(10), 878-890. doi:10.1016/S1474-4422(12)70205-3

    DOI: 10.1016/S1474-4422(12)70205-3

    Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations (Journal article)

    Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. Antimicrobial Agents and Chemotherapy, 56(2), 816-824. doi:10.1128/AAC.05186-11

    DOI: 10.1128/AAC.05186-11

    Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. (Journal article)

    Byakika-Kibwika, P., Lamorde, M., Okaba-Kayom, V., Mayanja-Kizza, H., Katabira, E., Hanpithakpong, W., . . . Merry, C. (2012). Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 67(5), 1217-1223. doi:10.1093/jac/dkr596

    DOI: 10.1093/jac/dkr596

    Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings. (Journal article)

    Sloan, D. J., Corbett, E. L., Butterworth, A. E., Mwandumba, H. C., Khoo, S. H., Mdolo, A., . . . Davies, G. R. (2012). Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings.. Journal of clinical microbiology, 50(7), 2315-2320. doi:10.1128/JCM.00043-12

    DOI: 10.1128/JCM.00043-12

    Patients accessing HIV treatment via sexual health services: what are the risks of the dual case-note system? (Journal article)

    Seden, K., Mathew, T., Bradley, M., Ferraro, C., Hall, E., Beeching, N. J., & Khoo, S. H. (2012). Patients accessing HIV treatment via sexual health services: what are the risks of the dual case-note system?. INTERNATIONAL JOURNAL OF STD & AIDS, 23(2), 99-104. doi:10.1258/ijsa.2011.011070

    DOI: 10.1258/ijsa.2011.011070

    Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study (Journal article)

    Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(3), 1427-1433. doi:10.1128/AAC.05599-11

    DOI: 10.1128/AAC.05599-11

    Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects (Journal article)

    Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2011). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. Antiviral Therapy, 17(1), 19-24. doi:10.3851/IMP1910

    DOI: 10.3851/IMP1910

    Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. (Journal article)

    Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.. Antiviral therapy, 17(1), 19-24. doi:10.3851/IMP1910

    DOI: 10.3851/IMP1910

    Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)

    Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.

    Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults (Journal article)

    Byakika-Kibwika, P., Lamorde, M., Mayito, J., Nabukeera, L., Namakula, R., Mayanja-Kizza, H., . . . Merry, C. (2012). Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy, 67(9), 2213-2221. doi:10.1093/jac/dks207

    DOI: 10.1093/jac/dks207

    Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults. (Journal article)

    Lamorde, M., Byakika-Kibwika, P., Boffito, M., Nabukeera, L., Mayito, J., Ogwal-Okeng, J., . . . Merry, C. (2012). Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.. Journal of acquired immune deficiency syndromes (1999), 60(3), 295-298. doi:10.1097/QAI.0b013e3182567a35

    DOI: 10.1097/QAI.0b013e3182567a35

    2011

    Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals (Journal article)

    Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67

    DOI: 10.1097/QAI.0b013e3182364c67

    Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. (Journal article)

    Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrobial agents and chemotherapy, 55(6), 2775-2782. doi:10.1128/AAC.00887-10

    DOI: 10.1128/AAC.00887-10

    Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology (Poster)

    Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.

    Therapeutic drug monitoring of darunavir/ritonavir in pregnancy. (Journal article)

    Murtagh, R., Else, L. J., Kuan, K. B., Khoo, S. H., Jackson, V., Patel, A., . . . Lambert, J. S. (2019). Therapeutic drug monitoring of darunavir/ritonavir in pregnancy.. Antiviral therapy, 24(3), 229-233. doi:10.3851/imp3291

    DOI: 10.3851/imp3291

    13 A-Z of drugs used in the treatment of opportunist infections in HIV (Appendix 1) (Journal article)

    Weston, R., & Khoo, S. (2011). 13 A-Z of drugs used in the treatment of opportunist infections in HIV (Appendix 1). HIV Medicine, 12, 112-139. doi:10.1111/j.1468-1293.2011.00944_14.x

    DOI: 10.1111/j.1468-1293.2011.00944_14.x

    Ageing with HIV: medication use and risk for potential drug-drug interactions (Journal article)

    Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Yerly, S. (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248

    DOI: 10.1093/jac/dkr248

    Aging with HIV: medication use and risk for potential drug-drug interactions (Journal article)

    Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . SWISS HIV Cohort Study, O. B. O. T. (2011). Aging with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother, 66(9), 2107-2111.

    Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals (Journal article)

    Byakika-Kibwika, P., Lamorde, M., Mayanja-Kizza, H., Khoo, S., Merry, C., & Van geertruyden, J. -P. (2011). Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals. Malaria Research and Treatment, 2011, 1-5. doi:10.4061/2011/703730

    DOI: 10.4061/2011/703730

    British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. (Journal article)

    Nelson, M., Dockrell, D., Edwards, S., BHIVA Guidelines Subcommittee., Angus, B., Barton, S., . . . Weston, R. (2011). British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011.. HIV medicine, 12 Suppl 2, 1-140. doi:10.1111/j.1468-1293.2011.00944_1.x

    DOI: 10.1111/j.1468-1293.2011.00944_1.x

    Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults (Journal article)

    Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., . . . Merry, C. (2011). Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. Chemotherapy Research and Practice, 2011, 1-4. doi:10.1155/2011/393976

    DOI: 10.1155/2011/393976

    Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)

    Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215

    DOI: 10.1093/infdis/jir215

    Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)

    Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215

    DOI: 10.1093/infdis/jir215

    Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals (Journal article)

    Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . AIDS, G. C. N. H. I. V. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087

    DOI: 10.1093/jac/dkr087

    Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. (Journal article)

    Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . for HIV/AIDS, G. C. N. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.. J Antimicrob Chemother, 66(6), 1332-1339.

    Interactions of tenofovir, lamivudine, abacavir and didanosine in primary human cells. (Journal article)

    Janneh, O., & Khoo, S. H. (2011). Interactions of tenofovir, lamivudine, abacavir and didanosine in primary human cells.. Pharmaceutics, 3, 326-337.

    Lopinavir/ritonavir population pharmacokinetics in neonates and infants (Journal article)

    Urien, S., Firtion, G., Anderson, S. T., Hirt, D., Solas, C., Peytavin, G., . . . Tréluyer, J. -M. (2011). Lopinavir/ritonavir population pharmacokinetics in neonates and infants. British Journal of Clinical Pharmacology, 71(6), 956-960. doi:10.1111/j.1365-2125.2011.03926.x

    DOI: 10.1111/j.1365-2125.2011.03926.x

    Lopinavir/ritonavir population pharmacokinetics in neonates and infants. (Journal article)

    Urien, S., Firtion, G., Anderson, S. T., Hirt, D., Solas, C., Peytavin, G., . . . Tréluyer, J. M. (2011). Lopinavir/ritonavir population pharmacokinetics in neonates and infants.. Br J Clin Pharmacol, 71(6), 956-960. doi:10.1111/j.1365-2125.2011.03926.x

    DOI: 10.1111/j.1365-2125.2011.03926.x

    Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin (Journal article)

    Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., . . . Merry, C. (2011). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66(1), 180-183. doi:10.1093/jac/dkq411

    DOI: 10.1093/jac/dkq411

    Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation (Journal article)

    Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. Antimicrobial Agents and Chemotherapy, 55(9), 4218-4223. doi:10.1128/AAC.01747-10

    DOI: 10.1128/AAC.01747-10

    Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid) (Journal article)

    Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ANTIVIRAL THERAPY, 16(8), 1139-1147. doi:10.3851/IMP1918

    DOI: 10.3851/IMP1918

    Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract (Journal article)

    Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antiviral Therapy, 16(8), 1149-1167. doi:10.3851/IMP1919

    DOI: 10.3851/IMP1919

    Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation. (Journal article)

    Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.. Antimicrobial agents and chemotherapy, 55(9), 4218-4223. doi:10.1128/AAC.01747-10

    DOI: 10.1128/AAC.01747-10

    Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)

    Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. The Journal of antimicrobial chemotherapy, 66(3), 635-640. doi:10.1093/jac/dkq468

    DOI: 10.1093/jac/dkq468

    Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)

    Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother, 66(3), 635-640.

    Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals (Journal article)

    Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67

    DOI: 10.1097/QAI.0b013e3182364c67

    Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort (Journal article)

    Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Prevention, U. -A. M. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLOS ONE, 6(2). doi:10.1371/journal.pone.0016800

    DOI: 10.1371/journal.pone.0016800

    Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir (Journal article)

    Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10

    DOI: 10.1128/AAC.00623-10

    Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies (Journal article)

    Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. Antimicrobial Agents and Chemotherapy, 55(6), 2775-2782. doi:10.1128/AAC.00887-10

    DOI: 10.1128/AAC.00887-10

    Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. (Journal article)

    Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrob Agents Chemother, 55(6), 2775-2782.

    Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors? (Journal article)

    Hill, A., Khoo, S., Boffito, M., & Back, D. (2011). Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors?. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), e137-e138. doi:10.1097/QAI.0b013e318237ccae

    DOI: 10.1097/QAI.0b013e318237ccae

    The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir (Journal article)

    Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir. Int J STD AIDS, 22, 11-14.

    The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir. (Journal article)

    Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir.. Int J STD AIDS, 22, 11-14.

    Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy (Journal article)

    Lambert, J., Else, L., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x

    DOI: 10.1111/j.1468-1293.2010.00865.x

    Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir (Journal article)

    Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. International Journal of STD & AIDS, 22(1), 11-14. doi:10.1258/ijsa.2009.009184

    DOI: 10.1258/ijsa.2009.009184

    2010

    Grapefruit-Drug Interactions (Journal article)

    Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-Drug Interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000

    DOI: 10.2165/11585250-000000000-00000

    Pharmacokinetic evaluation of etravirine. (Journal article)

    Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine.. Expert opinion on drug metabolism & toxicology, 6(12), 1575-1585.

    Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. (Journal article)

    Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . Khoo, S. (2010). Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.. Antimicrobial agents and chemotherapy, 54(7), 2965-2973.

    Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans (Journal article)

    Wakeham, K., Parkes-Ratanshi, R., Watson, V., Ggayi, A. -B., Khoo, S., & Lalloo, D. G. (2010). Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(2), 316-319. doi:10.1093/jac/dkp451

    DOI: 10.1093/jac/dkp451

    HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms (Journal article)

    Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02d

    DOI: 10.1097/FPC.0b013e328335b02d

    Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. (Journal article)

    Mackie, N. E., Phillips, A. N., Kaye, S., Booth, C., & Geretti, A. -M. (2010). Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.. The Journal of infectious diseases, 201(9), 1303-1307. doi:10.1086/651618

    DOI: 10.1086/651618

    Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS (Conference Paper)

    Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.

    Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. (Journal article)

    Wakeham, K., Parkes-Ratanshi, R., Watson, V., Ggayi, A., Khoo, S., & Lalloo, D. G. (2010). Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.. J Antimicrobial Chemother, 65(2), 316-319.

    Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes (Journal article)

    Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(5), 906-916. doi:10.1093/jac/dkq082

    DOI: 10.1093/jac/dkq082

    Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes (Journal article)

    Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy, 65(5), 906-916. doi:10.1093/jac/dkq082

    DOI: 10.1093/jac/dkq082

    Factors influencing lopinavir and atazanavir plasma concentration. (Journal article)

    Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . UK CHIC Steering Committee. (2010). Factors influencing lopinavir and atazanavir plasma concentration.. The Journal of antimicrobial chemotherapy, 65(1), 129-137. doi:10.1093/jac/dkp408

    DOI: 10.1093/jac/dkp408

    Factors influencing lopinavir and atazanavir plasma concentration. (Journal article)

    Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . on behalf of the UK CHIC Steering Committee.. (2010). Factors influencing lopinavir and atazanavir plasma concentration.. J Antimicrob Chemother, 65(1), 129-137.

    Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens (Conference Paper)

    Pushpakom, S., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.

    Grapefruit juice drug interactions (Journal article)

    Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit juice drug interactions. Drugs, 70(18), 2373-2407.

    Grapefruit-drug interactions (Journal article)

    Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-drug interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000

    DOI: 10.2165/11585250-000000000-00000

    Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease (Journal article)

    Milburn, H., Ashman, N., Davies, P., Doffman, S., Drobniewski, F., Khoo, S., . . . Snelson, C. (2010). Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax, 65(6), 559-570. doi:10.1136/thx.2009.133173

    DOI: 10.1136/thx.2009.133173

    Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. (Journal article)

    Milburn, H., Ashman, N., Davies, P., Doffman, S., Drobniewski, F., Khoo, S., . . . Snelson, C. (2010). Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.. Thorax., 65(6), 559-570.

    HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. (Journal article)

    Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.. Pharmacogenet Genomics, 20(2), 112-120.

    New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals (Journal article)

    Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Journal of Antimicrobial Chemotherapy, 65(6), 1079-1085. doi:10.1093/jac/dkq086

    DOI: 10.1093/jac/dkq086

    New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. (Journal article)

    Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.. J Antimicrob Chemother, 65(6), 1079-1085.

    Pharmacokinetic evaluation of etravirine (Journal article)

    Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion on Drug Metabolism & Toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811

    DOI: 10.1517/17425255.2010.535811

    Pharmacokinetic evaluation of etravirine. (Journal article)

    Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine.. Expert opinion on drug metabolism & toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811

    DOI: 10.1517/17425255.2010.535811

    Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3- (Journal article)

    Paediatric European Network for Treatment of AIDS PENTA Group au. (2010). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-. Antivir Ther, 15(3), 297-305.

    Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. (Journal article)

    Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189.

    Pharmacokinetics and drug–drug interactions of antiretrovirals: An update (Journal article)

    Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug–drug interactions of antiretrovirals: An update. Antiviral Research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017

    DOI: 10.1016/j.antiviral.2009.07.017

    Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults (Journal article)

    Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . Khoo, S. (2010). Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults. Antimicrobial Agents and Chemotherapy, 54(7), 2965-2973. doi:10.1128/AAC.01198-09

    DOI: 10.1128/AAC.01198-09

    Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults (Journal article)

    Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . on behalf of the DART trial team. (2010). Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Antimicrob Agents Chemother, 54(7), 2965-2973.

    Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)

    Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..

    Population Pharmacokinetic Modeling of the Association between 63396C->T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)

    Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C->T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/AAC.00781-10

    DOI: 10.1128/AAC.00781-10

    Population pharmacokinetic modelling of the association between 63396C->T Pregnane X Receptor polymorphism and unboosted atazanavir clearance (Journal article)

    Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population pharmacokinetic modelling of the association between 63396C->T Pregnane X Receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother, 54(12), 5242-5250.

    Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. (Journal article)

    Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Swiss HIV Cohort Study. (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.. Antiviral therapy, 15(3), 413-423. doi:10.3851/imp1540

    DOI: 10.3851/imp1540

    Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study (Journal article)

    Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Battegay, M. (2010). Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3), 413-423. doi:10.3851/IMP1540

    DOI: 10.3851/IMP1540

    Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2 (Conference Paper)

    Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.

    Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir (Journal article)

    Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.

    Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. (Journal article)

    Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir.. Antimicrob Agents Chemother, 55(2), 879-887.

    Recognition of Risk for Clinically Significant Drug Interactions among HIV‐Infected Patients Receiving Antiretroviral Therapy (Journal article)

    Evans‐Jones, J., Cottle, L., Back, D., Gibbons, S., Beeching, N., Carey, P., & Khoo, S. (2010). Recognition of Risk for Clinically Significant Drug Interactions among HIV‐Infected Patients Receiving Antiretroviral Therapy. Clinical Infectious Diseases, 50(10), 1419-1421. doi:10.1086/652149

    DOI: 10.1086/652149

    Response to planned treatment interruptions in HIV infection varies across childhood. (Journal article)

    Paediatric European Network for Treatment of AIDS. Group authors., & Khoo, S. (2010). Response to planned treatment interruptions in HIV infection varies across childhood.. AIDS., 24(2), 231-241.

    Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. (Journal article)

    Poerksen, G., Pollock, L., Moons, P., Chesshyre, E., Burger, D., Khoo, S., & Molyneux, E. (2010). Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.. Antivir Ther, 15(2), 343-350.

    Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30® tablets (Journal article)

    Poerksen, G., Pollock, L., Moons, P., Chesshyre, E., Burger, D., Khoo, S., & Molyneux, E. (2010). Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30® tablets. Antiviral Therapy, 15(3), 343-350. doi:10.3851/IMP1544

    DOI: 10.3851/IMP1544

    Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women (Journal article)

    Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Flaherty, J. P., Boffito, M., Namakula, R., . . . Scarsi, K. K. (2010). Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 345-350. doi:10.1097/QAI.0b013e3181e9871b

    DOI: 10.1097/QAI.0b013e3181e9871b

    Tenofovir disoproxil fumarate and the kidney in HIV-infected patients: the evidence thus far. (Journal article)

    Mohammed, I. D., Mohiuddin, A., Pirmohamed, M., & Khoo, S. (2010). Tenofovir disoproxil fumarate and the kidney in HIV-infected patients: the evidence thus far.. HIV Ther, 4(3), 345-359.

    Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy (Journal article)

    Else, L. J., Jackson, V., Brennan, M., Back, D. J., Khoo, S. H., Coulter-Smith, S., & Lambert, J. S. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV MEDICINE, 15(10), 604-610. doi:10.1111/hiv.12164

    DOI: 10.1111/hiv.12164

    Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds (Journal article)

    Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036

    DOI: 10.1016/j.jchromb.2010.03.036

    Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. (Journal article)

    Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.. J Chromatogr B Analyt Technol Biomed Life Sci, 878(19), 1455-1465.

    2009

    Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. (Journal article)

    Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. The Journal of antimicrobial chemotherapy, 64(6), 1251-1259. doi:10.1093/jac/dkp358

    DOI: 10.1093/jac/dkp358

    Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes (Journal article)

    Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. H. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(5), 1002-1007. doi:10.1093/jac/dkp335

    DOI: 10.1093/jac/dkp335

    Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes (Journal article)

    Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 64(5), 1002-1007.

    Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (Journal article)

    Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., . . . Owen, A. (2009). Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med, 10(5), 310-317.

    Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC (Journal article)

    Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 68(3), 375-380. doi:10.1111/j.1365-2125.2009.03462.x

    DOI: 10.1111/j.1365-2125.2009.03462.x

    Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC (Journal article)

    Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol, 68(3), 375-380.

    Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. (Journal article)

    Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.. The Journal of antimicrobial chemotherapy, 63(6), 1233-1243. doi:10.1093/jac/dkp102

    DOI: 10.1093/jac/dkp102

    Cytochrome P450 2B6 516G -> T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (Journal article)

    Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). Cytochrome P450 2B6 516G -> T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV MEDICINE, 10(5), 310-317. doi:10.1111/j.1468-1293.2008.00689.x

    DOI: 10.1111/j.1468-1293.2008.00689.x

    The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)

    Liptrott, N., Penny, M., Bray, P., Sathish, J., Khoo, S., Back, D., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x

    DOI: 10.1111/j.1476-5381.2008.00050.x

    Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. (Journal article)

    Seden, K., Back, D., & Khoo, S. (2009). Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.. The Journal of antimicrobial chemotherapy, 64(1), 5-8. doi:10.1093/jac/dkp152

    DOI: 10.1093/jac/dkp152

    Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)

    Dickinson, L., Khoo, S., & Back, D. (2009). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, (in pr.

    Drug-Drug Interactions Involving Antiretrovirals (Journal article)

    Seden, K., Back, D. J., & Khoo, S. H. (2009). Drug-Drug Interactions Involving Antiretrovirals. Journal of Antimicrobial Chemotherapy, (in pr.

    P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir (Journal article)

    Janneh, O., Anwar, T., Jungbauer, C., Kopp, S., Khoo, S. H., Back, D. J., & Chiba, P. (2009). P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. ANTIVIRAL THERAPY, 14(7), 965-974. doi:10.3851/IMP1399

    DOI: 10.3851/IMP1399

    Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers (Journal article)

    Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. Journal of Antimicrobial Chemotherapy, 63(6), 1233-1243. doi:10.1093/jac/dkp102

    DOI: 10.1093/jac/dkp102

    Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study (Journal article)

    Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. CLINICAL INFECTIOUS DISEASES, 48(11), E108-E116. doi:10.1086/598507

    DOI: 10.1086/598507

    Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study (Journal article)

    Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis, 48(11), e108-e116.

    The Relationships of ABCB1 3435C > T and CYP2B6 516G > T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz (Journal article)

    Mahungu, T. W., Nair, D., Smith, C. J., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). The Relationships of ABCB1 3435C > T and CYP2B6 516G > T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. CLINICAL PHARMACOLOGY & THERAPEUTICS, 86(2), 204-211. doi:10.1038/clpt.2009.78

    DOI: 10.1038/clpt.2009.78

    The role of therapeutic drug monitoring in treatment of HIV infection (Journal article)

    Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(4), 301-308. doi:10.1046/j.1365-2125.2001.01380.x

    DOI: 10.1046/j.1365-2125.2001.01380.x

    2008

    Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry (Journal article)

    Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010

    DOI: 10.1016/j.jim.2008.09.010

    Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals (Journal article)

    Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1344-1355. doi:10.1093/jac/dkn399

    DOI: 10.1093/jac/dkn399

    Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. (Journal article)

    Dickinson, L., Boffito, M., Back, D., Khoo, S., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.. The Journal of antimicrobial chemotherapy, 62(6), 1344-1355.

    Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir (Journal article)

    Janneh, O., Hartkoorn, R. C., Jones, E., Owen, A., Ward, S. A., Davey, R., . . . Khoo, S. H. (2008). Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. BRITISH JOURNAL OF PHARMACOLOGY, 155(6), 875-883. doi:10.1038/bjp.2008.320

    DOI: 10.1038/bjp.2008.320

    Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. (Journal article)

    Byakika-Kibwika, P., Lamorde, M., Kalemeera, F., D'Avolio, A., Mauro, S., Di Perri, G., . . . Merry, C. (2008). Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 62(5), 1113-1117. doi:10.1093/jac/dkn290

    DOI: 10.1093/jac/dkn290

    Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing (Journal article)

    Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(1), 161-167. doi:10.1093/jac/dkn187

    DOI: 10.1093/jac/dkn187

    Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing (Journal article)

    Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62(1), 161-167. doi:10.1093/jac/dkn187

    DOI: 10.1093/jac/dkn187

    Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. (Journal article)

    Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.. Therapeutic drug monitoring, 30(3), 306-313.

    Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis (Journal article)

    Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313.

    Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse‐Transcriptase Inhibitors in HIV Type 1–Infected Children (Journal article)

    Cressey, T., Green, H., Khoo, S., Treluyer, J., Compagnucci, A., Saidi, Y., . . . Burger, D. (2008). Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse‐Transcriptase Inhibitors in HIV Type 1–Infected Children. Clinical Infectious Diseases, 46(10), 1601-1608. doi:10.1086/587657

    DOI: 10.1086/587657

    Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)

    Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV and AIDS, 3(3), 296-305. doi:10.1097/COH.0b013e3282f82bf1

    DOI: 10.1097/COH.0b013e3282f82bf1

    Impact of CYP2B6 983T > C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients (Journal article)

    Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., . . . HIVAIDS, G. C. N. (2008). Impact of CYP2B6 983T > C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 914-918. doi:10.1093/jac/dkn029

    DOI: 10.1093/jac/dkn029

    Hypoadrenalism is not associated with early mortality during tuberculosis treatment in Malawi (Journal article)

    Beadsworth, M. B. J., van Oosterhout, J. J., Diver, M. J., Faragher, E. B., Shenkin, A., Mwandumba, H. C., . . . Zijlstra, E. E. (2008). Hypoadrenalism is not associated with early mortality during tuberculosis treatment in Malawi. International Journal of Tuberculosis and Lung Disease, 12(3), 314-318. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18284838

    Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C -> T) with reduced concentrations of unboosted atazanavir (Journal article)

    Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C -> T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304

    DOI: 10.1086/592304

    British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. (Journal article)

    Gazzard, B. G., Anderson, J., Babiker, A., Boffito, M., Brook, G., Brough, G., . . . BHIVA Treatment Guidelines Writing Group. (2008). British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.. HIV medicine, 9(8), 563-608. doi:10.1111/j.1468-1293.2008.00636.x

    DOI: 10.1111/j.1468-1293.2008.00636.x

    Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy? (Journal article)

    Winston, A., & Khoo, S. (2008). Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?. Current Opinion in HIV and AIDS, 3(6), 608-611. doi:10.1097/COH.0b013e328312972e

    DOI: 10.1097/COH.0b013e328312972e

    Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients (Journal article)

    Molto, J., Santos, J. R., Perez-Alvarez, N., Cedeno, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 52(11), 3928-3932. doi:10.1128/AAC.00520-08

    DOI: 10.1128/AAC.00520-08

    Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons (Journal article)

    Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV and AIDS, 3(3), 296-305. doi:10.1097/COH.0b013e3282f82bf1

    DOI: 10.1097/COH.0b013e3282f82bf1

    Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication (Journal article)

    Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . Khoo, S. (2008). Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication. Antiviral Therapy, 13(5), 675-685.

    Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. (Journal article)

    Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . UK CHIC Study. (2008). Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.. Antiviral therapy, 13(5), 675-685.

    Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis (Journal article)

    Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313. doi:10.1097/FTD.0b013e318177209e

    DOI: 10.1097/FTD.0b013e318177209e

    Pharmacogenetics of antiretroviral agents (Journal article)

    Owen, A., & Khoo, S. H. (2008). Pharmacogenetics of antiretroviral agents. CURRENT OPINION IN HIV AND AIDS, 3(3), 288-295. doi:10.1097/COH.0b013e3282f7cda4

    DOI: 10.1097/COH.0b013e3282f7cda4

    Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation (Journal article)

    Back, D., Else, L., Khoo, S., Boffito, M., Taylor, J., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. ANTIVIRAL THERAPY, 13(7), 901-907.

    Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. (Journal article)

    Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.. Antiviral therapy, 13(7), 901-907.

    2007

    A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin (Journal article)

    Hartkoorn, R. C., Khoo, S., Back, D. J., Tjia, J. F., Waitt, C. J., Chaponda, M., . . . Ward, S. A. (2007). A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 857(1), 76-82. doi:10.1016/j.jchromb.2007.07.005

    DOI: 10.1016/j.jchromb.2007.07.005

    Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)

    Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367. doi:10.1097/ftd.0b013e3180683b25

    DOI: 10.1097/ftd.0b013e3180683b25

    Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. (Journal article)

    Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367.

    Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy (Journal article)

    Kikaire, B., Khoo, S., Walker, A. S., Ssali, F., Munderi, P., Namale, L., . . . Grosskurth, H. (2007). Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS, 21(6), 733-737. doi:10.1097/QAD.0b013e3280121801

    DOI: 10.1097/QAD.0b013e3280121801

    Combining resistance and pharmacology for optimum patient care (Journal article)

    Khoo, S. H., Winston, A., & Back, D. J. (2007). Combining resistance and pharmacology for optimum patient care. CURRENT OPINION IN HIV AND AIDS, 2(3), 157-168. doi:10.1097/COH.0b013e3280f31d27

    DOI: 10.1097/COH.0b013e3280f31d27

    Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?' (Journal article)

    Hastings, I. M., Lalloo, D. G., & Khoo, S. H. (2007). Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'. AIDS, 21(2), 258-259. doi:10.1097/QAD.0b013e32801121fb

    DOI: 10.1097/QAD.0b013e32801121fb

    Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification (Journal article)

    Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(4), 881-884. doi:10.1093/jac/dkm281

    DOI: 10.1093/jac/dkm281

    Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein (Journal article)

    Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., & Khoo, S. H. (2007). Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. TUBERCULOSIS, 87(3), 248-255. doi:10.1016/j.tube.2006.12.001

    DOI: 10.1016/j.tube.2006.12.001

    Effect of transporter modulation on the emergence of nelfinavir resistance in vitro (Journal article)

    Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance in vitro. ANTIVIRAL THERAPY, 12(5), 831-834. Retrieved from http://gateway.webofknowledge.com/

    Effect of transporter modulation on the emergence of nelfinavir resistance in vitro (Journal article)

    Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance in vitro. Antivir Ther, 12(5), 831-834. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17713167

    Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects (Journal article)

    Chandler, B., Detsika, M., Khoo, S. H., Williams, J., Back, D. J., & Owen, A. (2007). Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(3), 685-689. doi:10.1093/jac/dkm230

    DOI: 10.1093/jac/dkm230

    HIV and pharmacogenomics in 2007 (Journal article)

    Khoo, S. (2007). HIV and pharmacogenomics in 2007. Pharmacogenomics, 8(1), 25-27. doi:10.2217/14622416.8.1.25

    DOI: 10.2217/14622416.8.1.25

    Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes (Journal article)

    Janneh, O., Jones, E., Chandler, B., Owen, A., & Khoo, S. H. (2007). Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(5), 987-993. doi:10.1093/jac/dkm353

    DOI: 10.1093/jac/dkm353

    Stopping antiretroviral therapy (Journal article)

    Taylor, S., Boffito, M., Khoo, S., Smit, E., & Back, D. (2007). Stopping antiretroviral therapy. AIDS, 21(13), 1673-1682. doi:10.1097/QAD.0b013e3281c61394

    DOI: 10.1097/QAD.0b013e3281c61394

    2006

    Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug (Journal article)

    Hider, S. L., Owen, A., Hartkoorn, R., Khoo, S., Back, D., Silman, A. J., & Bruce, I. N. (2006). Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. ANNALS OF THE RHEUMATIC DISEASES, 65(10), 1390-1393. doi:10.1136/ard.2005.049189

    DOI: 10.1136/ard.2005.049189

    Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV (Journal article)

    Friedland, G., Khoo, S., Jack, C., & Lalloo, U. (2006). Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal of Antimicrobial Chemotherapy, 58(6), 1299-1302. doi:10.1093/jac/dkl399

    DOI: 10.1093/jac/dkl399

    An update on therapeutic drug monitoring for antiretroviral drugs. (Journal article)

    Back, D., Gibbons, S., & Khoo, S. (2006). An update on therapeutic drug monitoring for antiretroviral drugs.. Therapeutic drug monitoring, 28(3), 468-473. doi:10.1097/01.ftd.0000211825.57984.41

    DOI: 10.1097/01.ftd.0000211825.57984.41

    Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response. (Journal article)

    Winston, A., Patel, N., Back, D., Khoo, S., Bulbeck, S., Mandalia, S., . . . Boffito, M. (2006). Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.. Journal of acquired immune deficiency syndromes (1999), 41(5), 675-676. doi:10.1097/01.qui.0000209910.27997.d9

    DOI: 10.1097/01.qui.0000209910.27997.d9

    Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. (Journal article)

    Ford, J., Boffito, M., Maitland, D., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2006). Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.. The Journal of antimicrobial chemotherapy, 58(5), 1009-1016. doi:10.1093/jac/dkl379

    DOI: 10.1093/jac/dkl379

    No room for complacency on drug resistance in Africa (Journal article)

    Hastings, I. M., Lalloo, D. G., & Khoo, S. H. (2006). No room for complacency on drug resistance in Africa. NATURE, 444(7115), 31. doi:10.1038/444031c

    DOI: 10.1038/444031c

    No room for complacency on drug resistance in Africa (Journal article)

    Hastings, I. M., Lalloo, D. G., & Khoo, S. (2006). No room for complacency on drug resistance in Africa. Nature, 444(7115), 31.

    Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. (Journal article)

    Davies, G. R., Khoo, S. H., & Aarons, L. J. (2006). Optimal sampling strategies for early pharmacodynamic measures in tuberculosis.. The Journal of antimicrobial chemotherapy, 58(3), 594-600. doi:10.1093/jac/dkl272

    DOI: 10.1093/jac/dkl272

    Pharmacogenetics of HIV therapy (Journal article)

    Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. PHARMACOGENETICS AND GENOMICS, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57

    DOI: 10.1097/01.fpc.0000236338.41799.57

    Pharmacogenetics of HIV therapy (Journal article)

    Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. Pharmacogenet Genomics, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57

    DOI: 10.1097/01.fpc.0000236338.41799.57

    Pharmacokinetics of reverse transcriptase inhibitors (Chapter)

    Hoggard, P., Kewn, S., Khoo, S., & Back, D. (2006). Pharmacokinetics of reverse transcriptase inhibitors. In G. Skowron, & R. Ogden (Eds.), Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (pp. xxx). Totowa, New Jersey: Humana Press.

    Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support (Journal article)

    Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 41(4), 461-467. doi:10.1097/01.qai.0000218345.65434.21

    DOI: 10.1097/01.qai.0000218345.65434.21

    Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support. (Journal article)

    Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support.. J Acquir Immune Defic Syndr, 41(4), 461-467.

    Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals (Journal article)

    Back, D. J., Owen, A., & Khoo, S. H. (2006). Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. CLINICAL PHARMACOKINETICS, 45(2), 213-214. doi:10.2165/00003088-200645020-00006

    DOI: 10.2165/00003088-200645020-00006

    Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. (Journal article)

    Davies, G. R., Brindle, R., Khoo, S. H., & Aarons, L. J. (2006). Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.. Antimicrobial agents and chemotherapy, 50(9), 3154-3156. doi:10.1128/AAC.00774-05

    DOI: 10.1128/AAC.00774-05

    Will ART rollout in Africa drive an epidemic of drug resistant HIV? (Journal article)

    Hastings, I. M., Lalloo, D., & Khoo, S. H. (2006). Will ART rollout in Africa drive an epidemic of drug resistant HIV?. AIDS, 20(9), 1354-1356. doi:10.1097/01.aids.0000232257.97027.80

    DOI: 10.1097/01.aids.0000232257.97027.80

    2005

    Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. (Journal article)

    Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90.

    Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals (Journal article)

    Almond, L. M., Hoggard, P. G., Edirisinghe, D., Khoo, S. H., & Back, D. J. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 56(4), 738-744. doi:10.1093/jac/dki308

    DOI: 10.1093/jac/dki308

    Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals (Journal article)

    Almond, L. M., Edirisinghe, D., Dalton, M., Bonington, A., Back, D. J., & Khoo, S. H. (2005). Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. CLINICAL PHARMACOLOGY & THERAPEUTICS, 78(2), 132-142. doi:10.1016/j.clpt.2005.04.004

    DOI: 10.1016/j.clpt.2005.04.004

    Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer. (Journal article)

    Hider, S. L., Hoggard, P., Khoo, S., Back, D., & Bruce, I. N. (2005). Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.. Arthritis and rheumatism, 52(2), 670. doi:10.1002/art.20770

    DOI: 10.1002/art.20770

    Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance (Journal article)

    Sadiq, S. T., Fredericks, S., Khoo, S. H., Rice, P., & Holt, D. W. (2005). Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS, 19(15), 1716-1717. doi:10.1097/01.aids.0000186828.99032.60

    DOI: 10.1097/01.aids.0000186828.99032.60

    In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine (Journal article)

    Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314(3), 1202-1209. doi:10.1124/jpet.105.086272

    DOI: 10.1124/jpet.105.086272

    In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine (Journal article)

    Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther, 314(3), 1202-1209.

    In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. (Journal article)

    Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.. The Journal of pharmacology and experimental therapeutics, 314(3), 1202-1209. doi:10.1124/jpet.105.086272

    DOI: 10.1124/jpet.105.086272

    Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)

    Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. doi:10.1097/01.aids.0000194793.36175.40

    DOI: 10.1097/01.aids.0000194793.36175.40

    Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)

    Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.

    Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)

    Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.

    Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)

    Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16284458

    Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13) (Journal article)

    Bergshoeff, A., Burger, D., Verweij, C., Farrelly, L., Flynn, J., Le Prevost, M., . . . Gibb, D. (2005). Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther, 10(2), 239-246. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15865218

    Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. (Journal article)

    Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90. doi:10.1016/j.jchromb.2005.09.032

    DOI: 10.1016/j.jchromb.2005.09.032

    The potential for interactions between antimalarial and antiretroviral drugs. (Journal article)

    Khoo, S., Back, D., & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs.. AIDS (London, England), 19(10), 995-1005. doi:10.1097/01.aids.0000174445.40379.e0

    DOI: 10.1097/01.aids.0000174445.40379.e0

    2004

    A British Second World War veteran with disseminated strongyloidiasis (Journal article)

    Gill, G. V., Beeching, N. J., Khoo, S., Bailey, J. W., Partridge, S., Blundell, J. W., & Luksza, A. R. (2004). A British Second World War veteran with disseminated strongyloidiasis. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 98(6), 382-386. doi:10.1016/j.trstmh.2003.11.002

    DOI: 10.1016/j.trstmh.2003.11.002

    Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation (Journal article)

    Behzad-Behbahani, A., Klapper, P., Vallely, P., Cleator, G., & Khoo, S. (2004). Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation. Journal of Clinical Virology, 29(4), 224-229. doi:10.1016/S1386-6532(03)00155-0

    DOI: 10.1016/S1386-6532(03)00155-0

    Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA (Journal article)

    Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. ANTIVIRAL THERAPY, 9(5), 819-821. Retrieved from http://gateway.webofknowledge.com/

    Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 (Journal article)

    Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., & Khoo, S. H. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. JOURNAL OF VIROLOGY, 78(21), 12022-12029. doi:10.1128/JVI.78.21.12022-12029.2004

    DOI: 10.1128/JVI.78.21.12022-12029.2004

    Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 (Journal article)

    Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D., & Khoo, S. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol, 78(21), 12022-12029.

    Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression (Journal article)

    Ford, J., Cornforth, D., Hoggard, P. G., Cuthbertson, Z., Meaden, E. R., Williams, I., . . . Khoo, S. H. (2004). Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. ANTIVIRAL THERAPY, 9(1), 77-84. Retrieved from http://gateway.webofknowledge.com/

    Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. (Journal article)

    Ford, J., Boffito, M., Wildfire, A., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2004). Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.. Antimicrobial agents and chemotherapy, 48(7), 2388-2393. doi:10.1128/AAC.48.7.2388-2393.2004

    DOI: 10.1128/AAC.48.7.2388-2393.2004

    Intracellular pharmacokinetics of antiretroviral agents. (Journal article)

    Owen, A., & Khoo, S. H. (2004). Intracellular pharmacokinetics of antiretroviral agents.. Journal of HIV therapy, 9(4), 97-101.

    Lopinavir protein binding in vivo through the 12-hour dosing interval (Journal article)

    Boffito, M., Hoggard, P. G., Lindup, W. E., Bonora, S., Sinicco, A., Khoo, S. H., . . . Back, D. J. (2004). Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit, 26(1), 35-39. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14749547

    Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen (Journal article)

    Isaac, A., Taylor, S., Cane, P., Smit, E., Gihbons, S. E., White, D. J., . . . Back, D. J. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54(2), 498-502. doi:10.1093/jac/dkh357

    DOI: 10.1093/jac/dkh357

    Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen (Journal article)

    Isaac, A., Taylor, S., Cane, P., Smit, E., Gibbons, S., White, D. J., . . . Back, D. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother, 54(2), 498-502.

    Pharmacology update: drug-drug interactions and ethnic and sex differences (Chapter)

    Back, D. J., Dickinson, L., Canta, F., & Khoo, S. (2004). Pharmacology update: drug-drug interactions and ethnic and sex differences. In HIV/AIDS Annual Update 2004. Clinical Care Options for HIV.

    The intracellular pharmacology of antiretroviral protease inhibitors (Journal article)

    Ford, J., Khoo, S. H., & Back, D. J. (2004). The intracellular pharmacology of antiretroviral protease inhibitors. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54(6), 982-990. doi:10.1093/jac/dkh487

    DOI: 10.1093/jac/dkh487

    The relationship between nevirapine plasma concentrations and abnormal liver function tests (Journal article)

    Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . Di Perri, G. (2004). The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS RESEARCH AND HUMAN RETROVIRUSES, 20(7), 716-722. doi:10.1089/0889222041524670

    DOI: 10.1089/0889222041524670

    Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis (Journal article)

    Joseph, A. T., & Khoo, S. H. (2004). Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis. International Journal of STD & AIDS, 15(1), 67-68. doi:10.1258/095646204322637335

    DOI: 10.1258/095646204322637335

    2003

    A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets (Journal article)

    Ford, J., Hoggard, P. G., & et, A. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods, 274(1-2), 129-137. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12609539

    British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). (Journal article)

    Gazzard, B., & BHIVA Writing Committee. (2005). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).. HIV medicine, 6 Suppl 2, 1-61. doi:10.1111/j.1468-1293.2005.0311b.x

    DOI: 10.1111/j.1468-1293.2005.0311b.x

    Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells (Journal article)

    Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells. J Infect Dis, 187(5). doi:10.1086/367902

    DOI: 10.1086/367902

    Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression (Journal article)

    Ford, J., Meaden, E. R., Hoggard, P. G., Dalton, M., Newton, P., Williams, I., . . . Back, D. J. (2003). Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 52(3), 354-358. doi:10.1093/jac/dkg381

    DOI: 10.1093/jac/dkg381

    Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients (Journal article)

    Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., . . . Back, D. J. (2003). Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 47(1), 255-261. doi:10.1128/AAC.47.1.255-261.2003

    DOI: 10.1128/AAC.47.1.255-261.2003

    Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines (Journal article)

    Owen, A., Hartkoorn, R. C., Khoo, S., & Back, D. (2003). Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines. AIDS, 17(15), 2276-2278. doi:10.1097/01.aids.0000088212.77946.65

    DOI: 10.1097/01.aids.0000088212.77946.65

    Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring (Journal article)

    Boffito, M., Back, D. J., Hoggard, P. G., Caci, A., Bonora, S., Raiteri, R., . . . Di Perri, G. (2003). Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS, 17(7), 1107-1108. doi:10.1097/01.aids.0000060372.78202.22

    DOI: 10.1097/01.aids.0000060372.78202.22

    Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes (Journal article)

    Janneh, O., Hoggard, P. G., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther, 8(5), 417-426. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14640389

    Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. (Journal article)

    Hennessy, M., Clarke, S., Spiers, J. P., Mulcahy, F., Kelleher, D., Meadon, E., . . . Barry, M. (2003). Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.. Antiviral therapy, 8(3), 191-198.

    Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting (Journal article)

    Boffito, M., Bonora, S., Sales, P., Dal Conte, I., Sinicco, A., Hoggard, P. G., . . . Di Perri, G. (2003). Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting. AIDS RESEARCH AND HUMAN RETROVIRUSES, 19(10), 941-942. doi:10.1089/088922203322493148

    DOI: 10.1089/088922203322493148

    Pharmacokinetic drug interactions with nevirapine (Journal article)

    Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr, 34 Sup, S8-S14. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14562853

    Pharmacokinetic drug interactions with nevirapine. (Journal article)

    Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine.. Journal of acquired immune deficiency syndromes (1999), 34 Suppl 1, S8-14. doi:10.1097/00126334-200309011-00003

    DOI: 10.1097/00126334-200309011-00003

    The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro (Journal article)

    Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr, 33(5), 551-556. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12902797

    The role of clinical pharmacology in optimizing antiretroviral therapy (Journal article)

    Back, D. J., & Khoo, S. H. (2003). The role of clinical pharmacology in optimizing antiretroviral therapy. Br J Clin Pharmacol, 55(5), 473-476. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12755810

    Therapeutic drug monitoring: help or hype? (Conference Paper)

    Khoo, S. H. (2003). Therapeutic drug monitoring: help or hype?. In The strategic use of resistance data. Proceedings of the Six HIV Reistance Workshop. London: Mediscript.

    Treating Advanced HIV Infection (Journal article)

    Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating Advanced HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(3), 344-345. doi:10.1097/00126334-200311010-00014

    DOI: 10.1097/00126334-200311010-00014

    Treating advanced HIV infection (Journal article)

    Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating advanced HIV infection. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 34(3), 344-345. doi:10.1097/00126334-200311010-00014

    DOI: 10.1097/00126334-200311010-00014

    2002

    Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo (Journal article)

    Meaden, E. R., Hoggard, P. G., Khoo, S. H., & Back, D. J. (2002). Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. JOURNAL OF IMMUNOLOGICAL METHODS, 262(1-2), 159-165. doi:10.1016/S0022-1759(02)00020-0

    DOI: 10.1016/S0022-1759(02)00020-0

    Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients (Journal article)

    Kewn, S., Hoggard, P. G., Sales, S. D., Jones, K., Maher, B., Khoo, S. H., & Back, D. J. (2002). Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(1), 135-143. doi:10.1128/AAC.46.1.135-143.2002

    DOI: 10.1128/AAC.46.1.135-143.2002

    Intracellular accumulation of human immunodeficiency virus protease inhibitors (Journal article)

    Khoo, S. H., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. J. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(10), 3228-3235. doi:10.1128/AAC.46.10.3228.2002

    DOI: 10.1128/AAC.46.10.3228.2002

    Intracellular accumulation of human immunodeficiency virus protease inhibitors (Journal article)

    Khoo, S., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother, 46(10), 3228-3235.

    P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals (Journal article)

    Meaden, E. R., Hoggard, P. G., Newton, P., Tjia, J. F., Aldam, D., Cornforth, D., . . . Khoo, S. H. (2002). P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 50(4), 583-588. doi:10.1093/jac/dkf161

    DOI: 10.1093/jac/dkf161

    Pharmacology (Chapter)

    Khoo, S., Back, D. J., & Merry, C. (2002). Pharmacology. In C. A. B. Boucher, & G. Galasso (Eds.), Practical guidelines in antiviral therapy (pp. vii, 344 p.). Amsterdam ; London: Elsevier.

    Therapeutic drug monitoring (Journal article)

    Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring. J Int Assoc Physicians AIDS Care (Chic), 1(3), 84-85.

    Therapeutic drug monitoring. (Journal article)

    Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring.. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 1(3), 84-85. doi:10.1177/154510970200100301

    DOI: 10.1177/154510970200100301

    Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea (Journal article)

    Hoggard, P. G., Kewn, S., Maherbe, A., Wood, R., Almond, L. M., Sales, S. D., . . . Khoo, S. H. (2002). Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS, 16(18), 2439-2446. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12461418

    2001

    Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport (Journal article)

    Jones, K., Hoggard, P. G., Sales, S. D., Khoo, S., Davey, R., & Back, D. J. (2001). Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS, 15(6), 675-681. doi:10.1097/00002030-200104130-00002

    DOI: 10.1097/00002030-200104130-00002

    Effect of alpha(1)-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro (Journal article)

    Jones, K., Hoggard, P. G., Khoo, S., Maher, B., & Back, D. J. (2001). Effect of alpha(1)-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(1), 99-102. doi:10.1046/j.1365-2125.2001.01324.x

    DOI: 10.1046/j.1365-2125.2001.01324.x

    Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients (Journal article)

    Meaden, E. R., Hoggard, P. G., Maher, B., Khoo, S. H., & Back, D. J. (2001). Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 17(14), 1329-1332. doi:10.1089/08892220152596588

    DOI: 10.1089/08892220152596588

    Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo (Journal article)

    Hoggard, P. G., Sales, S. D., Phiboonbanakit, D., Lloyd, J., Maher, B. A., Khoo, S. H., . . . Back, D. J. (2001). Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(2), 577-582. doi:10.1128/AAC.45.2.577-582.2001

    DOI: 10.1128/AAC.45.2.577-582.2001

    Novel IFN-α receptor promoter polymorphisms (Journal article)

    Muldoon, J., Uriel, A., Khoo, S., Ollier, W., & Hajeer, A. (2001). Novel IFN-α receptor promoter polymorphisms. Genes & Immunity, 2(3), 159-160. doi:10.1038/sj.gene.6363757

    DOI: 10.1038/sj.gene.6363757

    P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? (Journal article)

    Jones, K., Bray, P. G., Khoo, S. H., Davey, R. A., Meaden, E. R., Ward, S. A., & Back, D. J. (2001). P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. AIDS, 15(11), 1353-1358. doi:10.1097/00002030-200107270-00004

    DOI: 10.1097/00002030-200107270-00004

    The role of therapeutic drug monitoring in treatment of HIV infection (Journal article)

    Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 52, 89S-96S. Retrieved from http://gateway.webofknowledge.com/

    Therapeutic drug monitoring as a tool in treating HIV infection (Journal article)

    Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15, S171-S181. doi:10.1097/00002030-200100005-00021

    DOI: 10.1097/00002030-200100005-00021

    Therapeutic drug monitoring as a tool in treating HIV infection (Journal article)

    Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15 Sup, S171-S181. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11816166

    Zidovudine phosphorylation and mitochondrial toxicity in vitro (Journal article)

    Sales, S. D., Hoggard, P. G., Sunderland, D., Khoo, S., Hart, C. A., & Back, D. J. (2001). Zidovudine phosphorylation and mitochondrial toxicity in vitro. TOXICOLOGY AND APPLIED PHARMACOLOGY, 177(1), 54-58. doi:10.1006/taap.2001.9288

    DOI: 10.1006/taap.2001.9288

    Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents (Journal article)

    Hoggard, P. G., Lloyd, J., Khoo, S. H., Barry, M. G., Dann, L., Gibbons, S. E., . . . Back, D. J. (2001). Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(3), 976-980. doi:10.1128/AAC.35.3.976-980.2001

    DOI: 10.1128/AAC.35.3.976-980.2001

    2000

    Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro (Journal article)

    Hoggard, P. G., Sales, S. D., Kewn, S., Sunderland, D., Khoo, S. H., Hart, C. A., & Back, D. J. (2000). Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 11(6), 353-358. doi:10.1177/095632020001100601

    DOI: 10.1177/095632020001100601

    Current uses and future hopes for clinical pharmacology in the management of HIV infection (Journal article)

    Back, D., Khoo, S., Maher, B., & Gibbons, S. (2000). Current uses and future hopes for clinical pharmacology in the management of HIV infection. HIV Med, 1 Supp, 12-17. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11737367

    Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV-positive patients (Journal article)

    Lord, A., Bailey, A. S., Klapper, P. E., Snowden, N., & Khoo, S. H. (2000). Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV-positive patients. J Med Virol, 62(4), 405-409. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11074466

    Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers (Journal article)

    Wattanagoon, Y., Bangchang, K. N., Hoggard, P. G., Khoo, S. H., Gibbons, S. E., Phiboonbhanakit, D., . . . Back, D. J. (2000). Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 44(7), 1986-1989. doi:10.1128/AAC.44.7.1986-1989.2000

    DOI: 10.1128/AAC.44.7.1986-1989.2000

    Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection (Journal article)

    Back, D. J., Khoo, S. H., Gibbons, S. E., Barry, M. G., & Merry, C. (2000). Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. THERAPEUTIC DRUG MONITORING, 22(1), 122-126. doi:10.1097/00007691-200002000-00026

    DOI: 10.1097/00007691-200002000-00026

    1999

    Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively (Journal article)

    De Jong, J. C., Wermenbol, A. G., Verweij-Uijterwaal, M. W., Slaterus, K. W., Wertheim-Van Dillen, P., Van Doornum, G. J., . . . Hierholzer, J. C. (1999). Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol, 37(12), 3940-3945. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10565911

    The management of Pneumocystis carinii pneumonia (Journal article)

    Vilar, F. J., Khoo, S. H., & Walley, T. (1999). The management of Pneumocystis carinii pneumonia. Br J Clin Pharmacol, 47(6), 605-609. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10383536

    1998

    Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections (Journal article)

    Khoo, S. H., Hajia, M., Storey, C. C., Klapper, P. E., Wilkins, E. G., Denning, D. W., . . . Mandal, B. K. (1998). Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections. AIDS, 12(7), 751-757. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9619807

    1997

    Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro (Journal article)

    Hoggard, P. G., Kewn, S., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 41(6), 1231-1236. doi:10.1128/AAC.41.6.1231

    DOI: 10.1128/AAC.41.6.1231

    In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy (Journal article)

    Veal, G. J., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 13(6), 481-484. doi:10.1089/aid.1997.13.481

    DOI: 10.1089/aid.1997.13.481

    The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals (Journal article)

    Ng, T. T., Kanner, S. B., Humphries, M. J., Wickremasinghe, R. G., Nye, K. E., Anderson, J., . . . Morrow, W. J. (1997). The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals. J Immunol, 158(6), 2984-2999. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9058838

    Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression (Journal article)

    Khoo, S. H., Pepper, L., Snowden, N., Hajeer, A. H., Vallely, P., Wilkins, E. G., . . . Ollier, W. E. (1997). Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS, 11(4), 423-428. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9084788

    1996

    Induction of adrenal suppression by megestrol acetate (Journal article)

    Khoo, S. H., Wilkins, E. G., & Abbott, M. (1996). Induction of adrenal suppression by megestrol acetate. Ann Intern Med, 124(6), 613; author reply 614. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8597329

    Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation (Journal article)

    Veal, G. J., Hoggard, P. G., Barry, M. G., Khoo, S., & Back, D. J. (1996). Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS, 10(5), 546-548. doi:10.1097/00002030-199605000-00016

    DOI: 10.1097/00002030-199605000-00016

    Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency (Journal article)

    Pirmohamed, M., Williams, D., Tingle, M. D., Barry, M., Khoo, S. H., OMahony, C., . . . Park, B. K. (1996). Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency. AIDS, 10(5), 501-507. doi:10.1097/00002030-199605000-00008

    DOI: 10.1097/00002030-199605000-00008

    Intracellular metabolism of zidovudine and stavudine in combination. (Journal article)

    Hoggard, P., Khoo, S., Barry, M., & Back, D. (1996). Intracellular metabolism of zidovudine and stavudine in combination.. The Journal of infectious diseases, 174(3), 671-672. doi:10.1093/infdis/174.3.671

    DOI: 10.1093/infdis/174.3.671

    Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts (Journal article)

    Khoo, S. H., Wilkins, E. G., Fraser, I. S., Hamour, A. A., & Stanford, J. L. (1996). Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts. Thorax, 51(9), 932-935. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8984706

    The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites (Journal article)

    Barry, M. G., Khoo, S. H., Veal, G. J., Hoggard, P. G., Gibbons, S. E., Wilkins, E. G., . . . Back, D. J. (1996). The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS, 10(12), 1361-1367. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8902065

    1995

    Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology (Journal article)

    Khoo, S. H., Bailey, A. S., de Jong, J. C., & Mandal, B. K. (1995). Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology. J Infect Dis, 172(3), 629-637. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7658053

    Controversies in anti-retroviral therapy of adults (Journal article)

    Khoo, S. H., & Wilkins, E. G. (1995). Controversies in anti-retroviral therapy of adults. J Antimicrob Chemother, 35(2), 245-262. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7759389

    Cure of chronic invasive sinus aspergillosis with oral saperconazole (Journal article)

    Khoo, S. H., & Denning, D. W. (1995). Cure of chronic invasive sinus aspergillosis with oral saperconazole. J Med Vet Mycol, 33(1), 63-66. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7650581

    MARKED VARIATION IN PYRIMETHAMINE DISPOSITION IN AIDS PATIENTS TREATED FOR CEREBRAL TOXOPLASMOSIS (Journal article)

    WINSTANLEY, P., KHOO, S., SZWANDT, S., EDWARDS, G., WILKINS, E., TIJA, J., . . . BRECKENRIDGE, A. (1995). MARKED VARIATION IN PYRIMETHAMINE DISPOSITION IN AIDS PATIENTS TREATED FOR CEREBRAL TOXOPLASMOSIS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 36(2), 435-439. doi:10.1093/jac/36.2.435

    DOI: 10.1093/jac/36.2.435

    Prevalence of cortisol deficiency in late HIV disease (Journal article)

    Abbott, M., Khoo, S. H., Hammer, M. R., & Wilkins, E. G. (1995). Prevalence of cortisol deficiency in late HIV disease. J Infect, 31(1), 1-4. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8522825

    Safety and efficacy of combined meningococcal and typhoid vaccine (Journal article)

    Khoo, S. H., St Clair Roberts, J., & Mandal, B. K. (1995). Safety and efficacy of combined meningococcal and typhoid vaccine. BMJ, 310(6984), 908-909. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7719181

    1994

    Administering amphotericin B--a practical approach (Journal article)

    Khoo, S. H., Bond, J., & Denning, D. W. (1994). Administering amphotericin B--a practical approach. J Antimicrob Chemother, 33(2), 203-213. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8182001

    Invasive aspergillosis in patients with AIDS (Journal article)

    Khoo, S. H., & Denning, D. W. (1994). Invasive aspergillosis in patients with AIDS. Clin Infect Dis, 19 Sup, S41-S48. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7948570

    1993

    HIV induces deletion of T cell receptor variable gene product-specific T cells (Journal article)

    Bansal, A. S., Green, L. M., Khoo, S. H., Pumphrey, R. S., Haeney, M. R., & Mandal, B. K. (1993). HIV induces deletion of T cell receptor variable gene product-specific T cells. Clin Exp Immunol, 94(1), 17-20. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8403502

    Serum measurements of soluble CD23 in HIV infection (Journal article)

    Bansal, A. S., Pumphrey, R. S., Mandal, B. K., Khoo, S. H., & Wilson, P. B. (1993). Serum measurements of soluble CD23 in HIV infection. Immunology, 80(4), 652-653. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7905861

    1992

    Fulminant community acquired infections admitted to an intensive care unit (Journal article)

    Khoo, S. H., Creagh-Barry, P., Wilkins, E. G., & Pasvol, G. (1992). Fulminant community acquired infections admitted to an intensive care unit. Q J Med, 83(301), 381-388. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1438673

    Reactivation of tuberculous lymphadenitis during pregnancy (Journal article)

    Warner, T. T., Khoo, S. H., & Wilkins, E. G. (1992). Reactivation of tuberculous lymphadenitis during pregnancy. J Infect, 24(2), 181-184. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1569309

    Time to finish with "AIDS"? (Journal article)

    Khoo, S. H., Bailey, G., Wilkins, E. G., & Denning, D. W. (1992). Time to finish with "AIDS"?. Lancet, 339(8804), 1298. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1349694

    1991

    Northwick Park Infection Consultation Service. Part I. The aims and operation of the service and the general distribution of infection identified by the service between September 1987 and July 1990 [see comment] (Journal article)

    Wilkins, E. G., Hickey, M. M., Khoo, S., Hale, A. D., Umasankar, S., Thomas, P., . . . et, A. (1991). Northwick Park Infection Consultation Service. Part I. The aims and operation of the service and the general distribution of infection identified by the service between September 1987 and July 1990 [see comment]. J Infect, 23(1), 47-56. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1885912

    Northwick Park Infection Consultation Service. Part II. Contribution of the service to patient management: an analysis of results between September 1987 and July 1990 (Journal article)

    Wilkins, E. G., Hickey, M. M., Khoo, S., Hale, A. D., Umasankar, S., Thomas, P., . . . et, A. (1991). Northwick Park Infection Consultation Service. Part II. Contribution of the service to patient management: an analysis of results between September 1987 and July 1990. J Infect, 23(1), 57-63. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1885914

    Severe Helicobacter pylori infection in a patient with AIDS (Journal article)

    Khoo, S. H., & Blackwell, N. (1991). Severe Helicobacter pylori infection in a patient with AIDS. AIDS, 5(10), 1253-1255. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1786152

    Severe hyponatraemia in malaria (Journal article)

    Khoo, S. H., & Wilkins, E. G. (1991). Severe hyponatraemia in malaria. J Infect, 23(1), 85-87. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1885920